



how **someday**
becomes **today**

MICAYLA WYNN
CHRONIC MYELOID
LEUKEMIA SURVIVOR

**President
and
Chairman's
Message**



Louis J. DeGennaro, PhD
President & CEO



James H. Davis, PhD, JD
Chairman of the Board

Every day brings more proof of The Leukemia & Lymphoma Society's impact on the cancer treatment landscape, and our leadership was especially apparent in Fiscal Year 2015. New therapies for blood cancers are being discovered faster than ever before and those same treatments are also being tested for patients with other cancers like breast, colon and pancreatic cancer, and serious diseases like rheumatoid arthritis. And we continue to work diligently every day to ensure that all blood cancer patients have access to the treatments they so desperately need.

Thanks to you, The Leukemia & Lymphoma Society (LLS) is a driving force in making someday today for the more than 1.2 million people in the United States living with a blood cancer. From the strong science and advances in research you are helping us to spearhead, to wins in advocating for patients with legislators and policymakers, to helping newly diagnosed patients navigate their treatment, we continue to earn our leadership mantle as the voice for all blood cancer patients. Patients, caregivers and donors continually inspire us to keep investing in lifesaving breakthroughs.



We raised awareness about blood cancers and the LLS mission through a wide array of media and communications channels in Fiscal Year 2015. You'll see this, for example, in our support of the PBS documentary, *"Ken Burns Presents Cancer: The Emperor of All Maladies,"* which allowed LLS to showcase our historic role in advancing blood cancer treatments.

Our Therapy Acceleration Program continues to bridge the gap between discoveries in the laboratory and drug development, and this past year we entered into partnerships with even more biotechnology companies working on cutting-edge drug discovery and development programs. We continue to lead the charge against acute myeloid leukemia (AML) – now the most frequently diagnosed leukemia in adults – through the Harry T. Mangurian, Jr. Foundation Beat AML collaboration, changing the paradigm of how patients with AML are treated.

Fiscal Year 2015 also saw advances in therapies for patients with chronic lymphocytic leukemia (CLL), and a first-ever therapy indicated specifically for patients diagnosed with the rare Waldenstrom's macroglobulinemia.

We continued to help patients when they were diagnosed by providing critical support and information through our Information Resource Center, which received more than 60,000 calls from patients, families, and caregivers this past year alone. And, our advocacy efforts paid off this year with five additional states adopting oral parity legislation and the near unanimous passage in the U.S. House of Representatives of the 21st Century Cures Act, designed to reform and accelerate the drug discovery and development process.

As LLS's impact grows we see our important work not just helping patients with blood cancers, but reaching well beyond to help patients with other cancers and serious diseases as well. Treatments originally designed and tested in blood cancer patients are now being tested in other patients with diseases as diverse as pancreatic cancer and Parkinson's disease. We have made much progress, but there is more work to be done.

We are inspired every day by the researchers who are in a hurry to find cures, by thousands of volunteers across the country raising funds and supporting patients, by our dedicated staff across our 55 chapters on the frontlines with patients and families, and, most of all, by blood cancer patients waging heroic battles against these diseases. With your continued support, we will make someday today for more blood cancer patients and pave the way for treatments and cures across the cancer landscape.

Louis J. DeGennaro, PhD
President & CEO

James H. Davis, PhD, JD
Chairman of the Board

THERAPY ACCELERATION PROGRAM

LLS celebrated milestones achieved by several partners in our Therapy Acceleration Program (TAP), and introduced two new companies into the TAP portfolio in Fiscal Year 2015. We supported a total of 24 TAP partnerships in Fiscal Year 2015.

UNIVERSITY OF MICHIGAN

A promising University of Michigan research project, supported through TAP and focused on developing new treatments for patients with a rare and lethal subtype of leukemia, received a significant boost from a licensing agreement with a new biotechnology company, Kura Oncology. LLS has been funding this work, led by Assistant Professor Jolanta Grembecka, PhD, in collaboration with Tomasz Cierpicki, PhD, at the University of Michigan, since 2009. The research aims to develop new treatments for patients with leukemia associated with abnormalities in the mixed lineage leukemia (MLL) gene. These patients have a very poor prognosis with current therapies.

CELATOR PHARMACEUTICALS

LLS has been supporting the development of Celator Pharmaceuticals' CPX-351, a special formulation of two standard chemotherapy drugs, to treat patients with high-risk acute myeloid leukemia (AML). The therapy received a Fast Track Designation from the U.S. Food and Drug Administration, and interim data released from a Phase 3 clinical trial showed that CPX-351 performed better than standard therapy. LLS looks forward to seeing the overall survival data within the coming year.

ONCOPEP

LLS entered into a partnership with OncoPep to advance an experimental cancer vaccine that is designed to activate the immune system and control smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma.

Advancing Innovation in Research

The LLS research agenda is focused on finding cures. LLS drives research in areas of unmet medical need.





24 TAP Partnerships supported in FY15

The vaccine, PVX-410, was granted orphan drug designation by the U.S. Food and Drug Administration in 2013. LLS has committed to an equity investment of \$690,000 in the effort. A Phase 1/2 clinical trial is currently under way.

KITE PHARMA


LLS and Kite Pharma entered into a partnership to support a clinical trial for KTE-C19, a CAR-T (chimeric antigen receptor) immunotherapy for the treatment of patients with refractory non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy that genetically modifies patients' T cells to target a specific protein, CD19, on the cell surface of B-cell lymphomas and leukemias. Once activated, the T cells home in on and eliminate the cancer cells.

LLS'S VENTURE PHILANTHROPY IN THE MEDIA

LLS's venture philanthropy leadership in the cancer space garnered significant visibility in the October 2014 issue of *Health Affairs*, a leading peer-reviewed journal on health policy, thought and research. The article, "New Players Join the Drug Development Game," features our TAP prominently throughout.

In developing TAP, LLS recognized the need to take a more proactive role in order to accelerate the development of treatments and cures. The *Health Affairs* article noted that five of the small companies that LLS invested in later benefited from investment and licensing deals from large pharmaceutical companies.

**JOLANTA GREMBECKA, PhD,
PROFESSOR AND RESEARCHER
AT UNIVERSITY OF MICHIGAN**



BEAT AML

LLS continued to lead the charge against acute myeloid leukemia (AML) in Fiscal Year 2015, with its groundbreaking Harry T. Mangurian, Jr. Foundation Beat AML collaboration. LLS teamed up with Brian Druker, MD, and his research team at Oregon Health & Science University's Knight Cancer Institute in 2013 to accelerate the development of treatments for patients with AML. The researchers are deploying cutting-edge technology to create a profile of genetic defects in AML cells, and testing different drugs and drug combinations to determine the most effective treatments based on individual patients' particular genetic mutations. As we look to the next phase of the groundbreaking Beat AML initiative in the coming year, LLS anticipates that the innovative collaboration will prove to be a model for other cancer research and discovery programs. Generous donors have contributed more than \$8 million to support this initiative, including more than \$4 million from the Harry T. Mangurian, Jr., Foundation and more than \$300,000 raised through an online spring campaign.



THE EMPEROR OF ALL MALADIES

LLS was a proud supporter of the PBS documentary, *Ken Burns Presents "Cancer: The Emperor of All Maladies,"* a film by Barak Goodman. The film showcased a number of key treatment advances pioneered by LLS, including groundbreaking work in targeted

therapies for certain forms of leukemia. This brilliant history of cancer, based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, is really the story of LLS and blood cancers, and shows we are truly at a unique moment in our ability to treat and cure patients.

AMERICAN SOCIETY OF HEMATOLOGY

At the **56th American Society of Hematology (ASH) annual meeting**, more than 20,000 researchers from around the world converged in San Francisco to learn about the latest exciting advances in treating blood cancers. The LLS-funded team from University of Pennsylvania

277 academic grants funded in FY15

\$67.2 million **invested in research in FY15**

and The Children's Hospital of Philadelphia continued to demonstrate more evidence of the durability of chimeric antigen receptor T-cell (CAR-T) immunotherapy for patients with acute lymphoblastic leukemia (ALL).

During the treatment, the patient's immune T cells are engineered and then injected back into the patient to hunt and destroy cancer cells. After receiving the experimental treatment, 36 of 39 children (92%) with treatment-resistant ALL achieved a complete response. Six months after treatment, more than two-thirds (70%) of children enrolled in the study remained cancer free, and 75% have survived. Only five children have required subsequent treatment. The CAR-T approach, first pioneered in the blood cancers, is now being tested in other types of cancers, including breast, colon and pancreatic cancer and mesothelioma.

Other therapies showing promise are for patients with relapsed Hodgkin lymphoma (HL) and AML. The data with immune checkpoint inhibitors showed encouraging outcomes for patients with relapsed HL, which typically has a very poor prognosis. LLS is supporting this research as well.

An experimental approach to a therapy called IDH inhibitors showed promising, durable responses in patients with a subset of AML.

This is encouraging news for a disease that has not seen a change in the standard of therapy in the past 40 years. Researchers reported response rates of between 50% and 60% in refractory AML patients.

In addition, two research teams, one from Italy and one from the U.S., both supported by LLS, reported a high response rate in two separate studies of a precision medicine approach to treating patients diagnosed with hairy cell leukemia. Patients in both trials were treated with vemurafenib, a therapy that inhibits the BRAF gene mutation present in 95% of these patients.



LLS'S SATELLITE SYMPOSIUM AT ASH

LLS featured immunotherapy at its satellite symposium in advance of the 56th ASH Annual Meeting.

The symposium, "Emerging Immunotherapies for Hematologic Malignancies: Improving

Patient Outcomes by Harnessing the Immune System," featured renowned researchers and highlighted multiple approaches to stimulating the body's immune system to kill cancer cells. The standing-room-only crowd of more than 700 attendees was evidence of the overwhelming interest in this subject.

BLOOD CANCER DRUG APPROVALS IN FISCAL YEAR 2015

Ibrutinib for Waldenstrom's Macroglobulinemia

Breaking new ground, the U.S. Food and Drug Administration's approval of ibrutinib (Imbruvica®) for all patients with Waldenstrom's macroglobulinemia (WM) marked the first time a therapy was indicated specifically for patients with this rare diagnosis. Despite the numerous



LLS President and CEO Louis J. DeGennaro attends the 56th ASH Annual Meeting



currently utilized therapies to treat WM, until now there has been no standard of care for the disease and the current treatments are not curative.

The approval of ibrutinib, which is given as an oral pill, as both a first-line therapy and for those who have relapsed after other therapies, is a promising development, as recurrence is common. Ibrutinib had been approved for patients with CLL and mantle cell lymphoma the previous year, and is now being tested for patients with pancreatic cancer.

Idelalisib approved for CLL The U.S. Food and Drug Administration's approval of idelalisib to treat patients with relapsed CLL, follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) was a significant advance for patients, as the number of treatment options for patients continues to expand.

Idelalisib, an oral therapy indicated in combination with rituximab, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the proliferation of these cancer cells. LLS-funded research helped pave the way to such inhibitors of the PI3K pathway. In another example of how blood cancer research continues to lead the way for other cancers, other PI3K inhibitors are also being tested for the treatment of patients with solid tumors.

DANA-FARBER CELEBRATES 40 YEARS/\$60M INVESTMENT

Dana-Farber Cancer Institute recognized LLS's \$60 million investment in its blood cancer research programs over 40 years at a special event in April. At the event, some of the world's most accomplished physicians and scientists said that

LLS's investment in their work from the earliest days of their careers through the present allowed them to pursue with success areas of research for which they might not otherwise have had the resources.



conducted **clinical trial**
6,000 **searches for**
patients in FY15

Driving Policy Agenda: Federal and State Priorities

LLS recognizes that finding cures is not enough; we must ensure that patients have access to the treatments they need to live longer, better, healthier lives. LLS's Policy and Advocacy Team is dedicated to removing barriers to care.



ORAL PARITY BILLS

There are now 40 states with oral parity legislation on the books. Since 2012, LLS has helped to pass “oral parity” legislation in 20 of these states, removing barriers for patients who rely on prescription drugs to treat their cancer. LLS played a role in helping bills get passed in 5 states this past year alone: North Dakota, South Dakota, Mississippi, Wyoming and West Virginia.

21ST CENTURY CURES

LLS worked with Congress over the past year to help lawmakers develop the 21st Century Cures bill, a bipartisan Congressional initiative to invest in medical research and remove outdated impediments

that slow the discovery and development of new therapies. In addition to LLS President and CEO Louis J. DeGennaro’s testimony during a House committee roundtable on personalized medicine, LLS advocates engaged their elected officials in Washington, D.C., and in their home states. The House approved the act with an overwhelming majority in July. Similar legislation is now being developed in the Senate for consideration this coming year.

MILLIMAN REPORT AND OUT-OF-POCKET COSTS FOR PATIENTS

LLS commissioned a study from Milliman Inc., which found that placing limits on out-of-pocket costs for patients would relieve their financial burden without imposing a significant impact on insurers. The study, which used examples of insurance plans available on health insurance exchanges across the country established by the Affordable Care Act, reinforces LLS’s efforts to advocate for state and federal legislation that helps to control patient out-of-pocket costs.

**LLS ADVOCACY LEADERS CAME TO D.C.
AND HELPED THE 21ST CENTURY CURES ACT
PASS IN THE HOUSE**

CO-PAY ASSISTANCE

LLS's Co-Pay Assistance Program helps eligible patients with qualifying diagnoses pay their insurance premiums and meet co-pay obligations. LLS provided \$41.8 million for patients in Fiscal Year 2015 to help them afford these costs.

PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM

The *Patti Robinson Kaufmann First Connection Program* is a peer-to-peer program that matches newly diagnosed patients and their families with trained volunteers who have been touched firsthand by a blood cancer and share similar experiences. In Fiscal Year 2015, the free service matched well over 1,000 patients with trained volunteers.

INFORMATION RESOURCE CENTER

LLS's Information Resource Center (IRC) is a toll-free call center staffed by master's level healthcare professionals equipped with the latest information on all of the blood cancers. IRC specialists responded to approximately 60,000 inquiries in Fiscal Year 2015, more than half related to financial hardship. Information specialists can be reached at (800) 955-4572 from 9 a.m. to 9 p.m. ET Monday through Friday.

Helping Patients Gain Access to Care

LLS is the leading source of free, highly specialized blood cancer information, education and support for patients, survivors, families and healthcare professionals.



**BEATRICE ABETTI
LCSW, DIRECTOR OF LLS'S
INFORMATION RESOURCE CENTER**

Advancing Innovation in Fundraising

As a nonprofit, LLS relies on the generosity of individuals, corporations and foundations.

LIGHT THE NIGHT WELCOMES CHARLES ESTEN AS AMBASSADOR

In Fall 2014, friends, families and companies walked in LLS's Light The Night® Walks in approximately 180 venues around the country, and raised \$58.6 million to support LLS's mission. Actor and musician Charles Esten joined LLS as the National Light The Night Walk honorary chair. Thankful for his daughter Addie's recovery from childhood leukemia, Esten aimed to inspire other individuals, families and teams with his and Addie's appearances in national public



Light The Night Honorary Chair, actor and musician Charles Esten and daughter Addie

service announcements, radio segments and extensive educational materials promoting the Light The Night campaign. The Esten family also participated in the Light The Night Walk in their hometown of Nashville. Addie is living proof of LLS's impact on blood cancer patients and their families. Her experience demonstrates that funds raised for research can result in lifesaving treatments and cures.

LIGHT THE NIGHT WALK / BURLINGTON

Burlington Stores has been supporting LLS's Light The Night Walk campaign for the past 13 years. And in Fall 2014, for the 11th consecutive year, Burlington Stores was the largest national partner for Light The Night Walk. With a 15-week, in-store promotion, Burlington raised more than \$3 million. Since the partnership began, Burlington, a national off-price retailer, has collected more than \$22 million to help LLS advance therapies for blood cancer research and ensure patients have access to lifesaving treatments.

LEUKEMIA CUP REGATTA AND TIMEX

In Fiscal Year 2015, sailing enthusiasts who participated in LLS's Leukemia Cup Regatta raised nearly \$3.8 million for the LLS mission, culminating with a Fantasy Sail with Gary Jobson to take place in Bermuda in October 2015. Timex®, the world's leading global watch manufacturer, joined LLS as a national sponsor of the Leukemia Cup Regatta. Throughout calendar year 2015, Timex had a presence at events in support of LLS in the fight against cancer. The company also donated to LLS a percentage of the sales of its Yacht Racer watch.





Suja Rock 'n' Roll San Diego Marathon & 1/2 Marathon
Team In Training Participants

TEAM IN TRAINING

Team In Training® (TNT) continues to deliver a meaningful fundraising and training experience to individuals who have a desire to move the LLS mission forward. In Fiscal Year 2015, more than 12,500 TNT participants came together to raise \$41.8 million to support blood cancer research and patient services. TNT means corporate teams, community teams, passionate athletes, dedicated mission-minded fundraisers, online and social teams and more under one big TNT tent. The \$1.4 billion dollars raised by TNT participants over 27 years has helped drive blood cancer survival rates to new heights. Go TEAM!

STUDENT SERIES

In Fiscal Year 2015, the combined Student Series (formerly known as School & Youth Programs) Pennies for Patients and Pasta for Pennies presented by Olive Garden raised a total of \$27.7 million. Nearly 14.5 million students in 28,000 schools learned about service, leadership and philanthropy, and saw firsthand how their involvement made a difference in helping save the lives of blood cancer patients.

MAN & WOMAN OF THE YEAR

The 2015 Man & Woman of the Year campaign broke yet another record, with candidates raising more than \$32.5 million to help end blood cancer. In the 25th year of this prestigious program, more than 900 participants from across the country competed for the coveted national title. Man of the Year **Jason Fleischer** of New York used creative techniques such as a cornhole tournament and a date auction to raise \$302,045. The Woman of the Year, **Erin Ragsdale** of Texas, used her personal connections to elicit large donations that propelled her to a record-setting \$469,159. Campaign donations totaled \$1.7 million more than the previous year.

We also recognized our “All Star” alumni this year. This year the “All Star” winners were Summer Hall, from Davidson, NC, and Gary Cohen, from Hillsdale, NJ. Hall is a longtime LLS volunteer and mother who raised an “All Star” record of \$167,000 for a world without blood cancers. Gary Cohen, a TNT alumnus, raised \$62,335 to help eradicate blood cancers worldwide.



**MAN & WOMAN OF THE YEAR WINNERS
JASON FLEISCHER
AND ERIN RAGSDALE**

ONLINE FUNDRAISING AND LAUNCH OF NEW WEBSITE

Charitable giving continued its migration online during Fiscal Year 2015, growing by 9% as compared to an industry overall growth rate of 2%. LLS was well ahead of that trend, with online donations growing 22% year over year, as we focused our digital strategy on streamlining our digital donation path and adapting our platforms to increasingly mobile-focused consumer behavior.

LLS.org relaunched in May with a new design and new technology that allows patients, professionals and supporters easier access to the wealth of content and support offered, whether they're working at their desk, or have just left their doctor's office and are urgently seeking information on their mobile phone.

The new site has improved functionality and clearer navigation to discussion, support and research pages. Visitors also see stories and photos of survivors, caregivers and volunteers, and have a chance to submit their own. The migration of all our campaign sites to a similar platform is under way and will be complete by the middle of our next fiscal year.



BLOOD CANCER AWARENESS MONTH

During Blood Cancer Awareness Month, LLS continued to ramp up its efforts to reach new audiences of participants and donors, as well as patients. The integrated marketing and communications campaign, featuring LLS President and CEO Louis J. DeGennaro, launched across TV, radio and digital channels, including our website, and created the strongest awareness yet for LLS. Our targeted call to action garnered donations of \$433,000 through our website.





UNITED FOOD AND COMMERCIAL WORKERS UNION (UFCW)

The UFCW continued to grow its 32-year partnership with LLS, by connecting its Locals to our chapters in 20 markets to support LLS's Light The Night Walk. It was a banner year for the UFCW's commitment to LLS with an astounding \$4,350,000 raised through Light The Night and the myriad other fundraising events the union holds to benefit LLS, including golf tournaments, dinners, auctions, clay shoots and more. UFCW members affiliated with The Beer Store supported a bottle drive for LLSC in Ontario.

This initiative alone raised more than \$1.7 million.

The UFCW has raised close to \$77 million since 1983, and all funds raised by its more than 120 Locals in the U.S. and Canada are restricted to fund lifesaving research.

We salute new UFCW President Marc Perrone and the more than 1.3 million UFCW members for their tireless support and extraordinary commitment.

DONOR DEVELOPMENT – FUNDING THE MISSION

Donors were exceptionally generous with direct gifts of \$27.9 million. A highlight was the completion of the \$8.3 million fundraising campaign to Beat AML. This pioneering effort was sparked by a lead gift of \$4 million from the Harry T. Mangurian, Jr. Foundation, and further advanced by long-time LLS volunteer Michael Copley, who served as National Chair. Under his leadership, generous donors across the country recognized the value of this effort and brought us to the fundraising finish line in two years, a full year earlier than expected.

Major Gift donors of \$10,000 or more, who are listed in the pages of this report, funded many other mission-critical programs, ranging from new research in pediatric blood cancers to patient support through a Transportation Assistance Fund. And forward-looking individuals who chose to shape the future through their estate plans provided \$10.2 million in resources this year with thoughtful bequests.

**LIGHT THE NIGHT BURLINGTON'S
RETAIL IN-STORE CAMPAIGN MODELS –
CANCER SURVIVORS SHAYNE AND CHASE**

RESEARCH GRANTS

SPECIALIZED CENTER OF RESEARCH

The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hasten the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of Medical Research

Frederick Alt, PhD 2012
Immune Disease Institute

Jon Aster, MD 2013
Brigham and Women's Hospital

John Byrd, MD 2011¹
The Ohio State University

William Carroll, MD 2014²
New York University School of Medicine

Irene Ghobrial, MD 2014³
Dana-Farber Cancer Institute

Anthony Green, MD, PhD 2012
University of Cambridge

Helen Heslop, MD 2014⁴
Baylor College of Medicine

Carl June, MD 2013⁵
University of Pennsylvania

Thomas Kipps, MD, PhD 2014⁶
University of California, San Diego

Jonathan Licht, MD 2013
Northwestern University

CAREER DEVELOPMENT PROGRAM (SCHOLARS AND CLINICAL SCHOLARS)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Gregory Abel, MD 2013
Dana-Farber Cancer Institute

K Mark Ansel, PhD 2013
University of California, San Francisco

Uttiya Basu, PhD 2016*
Columbia University Medical Center

Julie Blander, PhD 2015
Icahn School of Medicine at Mount Sinai

Ivan Borrello, MD 2008⁷
The Johns Hopkins University School of Medicine

Patrick Brown, MD 2012⁸
Icahn School of Medicine at Mount Sinai

Jan Burger, MD, PhD 2014
The University of Texas MD Anderson Cancer Center

George Calin, MD 2012
The University of Texas MD Anderson Cancer Center

Fernando Camargo, PhD 2016*
Boston Children's Hospital

Iain Cheeseman, PhD 2013
Whitehead Institute for Biomedical Research

Dipanjan Chowdhury, PhD 2015
Dana-Farber Cancer Institute

Christopher Cogle, MD 2013
University of Florida

Yali Dou, PhD 2013
University of Michigan

Benjamin Ebert, MD, PhD 2013
Brigham and Women's Hospital

Thomas Fazio, PhD 2015
University of Massachusetts Medical School

Elsa Flores, PhD 2012
The University of Texas MD Anderson Cancer Center

Benjamin Garcia, PhD 2016*
Perelman School of Medicine at the University of Pennsylvania

Ramiro Garzon, MD 2016*
The Ohio State University

Andrei Goga, MD, PhD 2013
University of California, San Francisco

Ananda Goldrath, PhD 2012
University of California, San Diego

Jolanta Grembecka, PhD 2014⁹
University of Michigan

David Guertin, PhD 2016*
University of Massachusetts Medical School

Jonathan Higgins, PhD 2012
Newcastle University

Morgan Huse, PhD 2015
Memorial Sloan Kettering Cancer Center

Holbrook Kohrt, MD, PhD 2015¹⁰
The Board of Trustees of the Leland Stanford Junior University

Marina Konopleva, MD, PhD 2012
The University of Texas MD Anderson Cancer Center

John Koreth, MD, PhD 2014¹¹
Dana-Farber Cancer Institute

Ross Levine, MD 2013
Memorial Sloan Kettering Cancer Center

Ming Li, PhD 2015
Memorial Sloan Kettering Cancer Center

Ivan Maillard, MD, PhD 2014
University of Michigan

Ravindra Majeti, MD, PhD 2016*
The Board of Trustees of the Leland Stanford Junior University

Sami Malek, MD 2012
University of Michigan

Hanna Mikkola, MD, PhD 2012¹²
University of California, Los Angeles

Golam Mohi, PhD 2014
SUNY Upstate Medical Center

James Mulloy, PhD 2011¹³
Cincinnati Children's Hospital Medical Center

Ryoma Ohi, PhD 2014
Vanderbilt University Medical Center

Sophie Paczesny, MD, PhD 2015
Indiana University

Emmanuelle Passegué, PhD 2013
University of California, San Francisco

Cathie Pflieger, PhD 2013
Icahn School of Medicine at Mount Sinai

Joel Pomerantz, PhD 2012
Icahn School of Medicine at Mount Sinai

Loredana Ruggeri, MD, PhD 2011¹⁴
University of Perugia

Talya Salz, PhD 2014
Memorial Sloan Kettering Cancer Center

Joseph Scandura, MD, PhD 2014
Weill Cornell Medical College

Tait Shanafelt, MD 2013
Mayo Clinic

Jane Skok, PhD 2011¹⁵
New York University School of Medicine of Medical Research

Merav Socolovsky, MD, PhD 2013
University of Massachusetts Medical School

Daniel Starczynowski, PhD 2016*
Cincinnati Children's Hospital Medical Center

Kimberly Stegmaier, MD 2014
Dana-Farber Cancer Institute

Ulrich Steidl, MD, PhD 2015
Albert Einstein College of Medicine

Enrico Tiacci, MD 2014
University of Perugia

Raoul Tibes, MD, PhD 2015
Mayo Clinic Arizona

Wei Tong, PhD 2014
The Children's Hospital of Philadelphia

David Traver, PhD 2013
University of California, San Diego

Christopher Vakoc, MD, PhD 2016*
Cold Spring Harbor Laboratory

Amit Verma, MD 2013
Albert Einstein College of Medicine of Yeshiva University

Loren Walensky, MD, PhD 2015¹⁶
Dana-Farber Cancer Institute

Roland Walter, MD, PhD, MS 2015
Fred Hutchinson Cancer Research Center

Matthew Walter, MD 2014
Washington University School of Medicine in St. Louis

Hengbin Wang, PhD 2013
The University of Alabama at Birmingham

Wenyi Wei, PhD 2014
Beth Israel Deaconess Medical Center

David Weinstock, MD 2014
Dana-Farber Cancer Institute

Hans-Guido Wendel, MD 2015
Memorial Sloan Kettering Cancer Center

Johnathan Whetstine, PhD 2015
Massachusetts General Hospital

Catherine Wu, MD 2015
Dana-Farber Cancer Institute

Xiaochun Yu, MD, PhD 2015
University of Michigan

Shan Zha, MD, PhD 2014
Columbia University Medical Center

Chengcheng Zhang, PhD 2014
UT Southwestern Medical Center

Jing Zhang, PhD 2014¹⁷
University of Wisconsin-Madison

Xiaolan Zhao, PhD 2014
Memorial Sloan Kettering Cancer Center

Lee Zou, PhD 2012
Massachusetts General Hospital

Elna Zuniga, PhD 2013
University of California, San Diego

¹ Dr. John Byrd is funded in part by Rita Cavanagh & Gerald Kafka, Phyllis & Douglas A. Smith, and Judy & Michael H. Thomas.

² Dr. William Carroll is funded in part by Jane Elissa/Charlotte Meyers Endowment Fund.

³ Dr. Irene Ghobrial is funded in part by the Edwards P. Evans Foundation.

⁴ Dr. Helen Heslop is funded in part by Lee Goodwin & Linda Schwartzstein.

⁵ Dr. Carl June is funded in part by Beckman Coulter Foundation.
⁶ Dr. Thomas Kipps is funded in part by Harvey & Yetta Saltzman.

⁷ Dr. Ivan Borello is funded in part by Lee Goodwin & Linda Schwartzstein.
⁸ Dr. Stephen Grupp is funded in part by HM Insurance Group for his work under Carl June's SCOR grant.

⁹ Dr. Jolanta Grembecka is funded in part by Jennifer & Jeff Butler.

¹⁰ Dr. Holbrook Kohrt is funded in part by The Adami-Robertson Family.

¹¹ Dr. John Koreth is fully funded by The Orokawa Foundation.

¹² Dr. Hanna Mikkola is funded in part by Parents Against Leukemia.

¹³ Dr. James Mulloy is funded in part by The Marge & Charles J. Schott Foundation and the Cincinnati Golfers for Charity.

¹⁴ Dr. Loredana Ruggeri is funded in part by an anonymous donor.

¹⁵ Dr. John Koreth is fully funded by an anonymous donor.

¹⁶ Dr. Hanna Mikkola is funded in part by Parents Against Leukemia.

¹⁷ Dr. James Mulloy is funded in part by The Marge & Charles J. Schott Foundation and the Cincinnati Golfers for Charity.

¹⁸ Dr. Loredana Ruggeri is funded in part by an anonymous donor.

RESEARCH GRANTS (CONTINUED)

CAREER DEVELOPMENT PROGRAM (SPECIAL FELLOWS, CLINICAL SPECIAL FELLOWS, AND FELLOWS)

Alison Adams, PhD 2014
Yale University

Koshi Akahane, MD, PhD 2014
Dana-Farber Cancer Institute

Spencer Alford, PhD 2015
The Board of Trustees of the Leland Stanford Junior University

Burton Barnett, PhD 2015
University of California, San Diego

Cora Bergantinos, PhD 2015
Columbia University Medical Center

Ami Bhatt, MD, PhD 2014
Dana-Farber Cancer Institute

Jessica Blackburn, PhD 2014
Massachusetts General Hospital

Andres Blanco, PhD 2015
Boston Children's Hospital

Nicholas Brown, PhD 2016*
St. Jude Children's Research Hospital

Marcella Cesana, PhD 2015
Boston Children's Hospital

Tiffany Chang, MD 2014¹⁸
University of California, San Francisco

Michael Chu, MD 2015
The Board of Trustees of the Leland Stanford Junior University

Ahmet Coskun, PhD 2016*
California Institute of Technology

Dan Dominissini, PhD 2016*
The University of Chicago

Zhixun Dou, PhD 2015
University of Pennsylvania

Jonathan Driver, PhD 2014
University of Washington

Cihangir Duy, PhD 2013¹⁹
Weill Cornell Medical College

Chen Fang, PhD 2014²⁰
Fred Hutchinson Cancer Research Center

Eva Fast, PhD 2015
President & Fellows of Harvard College

Craig Forester, MD 2016*
University of California, San Francisco

Xiaofei Gao, PhD 2014
Whitehead Institute for Biomedical Research

Jacqueline Garcia, MD 2015
Dana-Farber Cancer Institute

Charles Gawad, MD 2014²¹
The Board of Trustees of the Leland Stanford Junior University

Luke Gilbert, PhD 2014
University of California, San Francisco

Stephanie Grainger, PhD 2015
University of California, San Diego

Sarah Hainer, PhD 2014
University of Massachusetts Medical School

Alexandre Iannello, PhD 2014
University of California, Berkeley

Andrew Intlekofer, MD 2016*
Memorial Sloan Kettering Cancer Center

Caron Jacobson, MD 2014
Dana-Farber Cancer Institute

Ana Janic, PhD 2014
Walter & Eliza Hall Institute of Medical Research

Stephanie Johnson, PhD 2015
University of California, San Francisco

Brian Jonas, MD, PhD 2013
The Board of Trustees of the Leland Stanford Junior University

Neeraj Joshi, PhD 2016*
University of California, San Francisco

Christopher Kanakry, MD 2014
Johns Hopkins University

Michael Khodadoust, MD, PhD 2015

The Board of Trustees of the Leland Stanford Junior University

Seoyoung Kim, PhD 2015
Memorial Sloan Kettering Cancer Center

Maria Kleppe, PhD 2014
Memorial Sloan Kettering Cancer Center

Latika Kohli, PhD 2015
University of California, San Francisco

Andrew Lane, MD, PhD 2013
Dana-Farber Cancer Institute

I-Ju Lee, PhD 2016*
Dana-Farber Cancer Institute

Qiming Liang, PhD 2016*
University of Southern California

Xiangyu Liu, PhD 2014
Columbia University Medical Center

Michael Lofgren, PhD 2015
Harvard Medical School

Marko Lööke, PhD 2015
Massachusetts Institute of Technology

Sidinh Luc, PhD 2014
Boston Children's Hospital

Zhuojuan Luo, PhD 2014
Northwestern University

Julia Maxson, PhD 2014
Fred Hutchinson Cancer Research Center

Jeffrey McKnight, PhD 2014
Fred Hutchinson Cancer Research Center

Marsilius Mues, PhD 2015
University of California, San Francisco

Vera Mugoni, PhD 2016*
Beth Israel Deaconess Medical Center

Jagan Muppidi, MD 2016*
University of California, San Francisco

Thang Nguyen, PhD 2014
California Institute of Technology

Kyla Omilusik, PhD 2013
University of California, San Diego

Ana Ortega Molina, PhD 2014
Memorial Sloan Kettering Cancer Center

Wen Pan, PhD 2015
Yale University

Lars Plate, PhD 2016*
The Scripps Research Institute

Heather Pua, MD, PhD 2014
University of California, San Francisco

Sarwish Rafiq, PhD 2014²²
Memorial Sloan Kettering Cancer Center

Kaushik Raganathan, PhD 2014
Harvard Medical School

Parvathi Ranganathan, PhD 2014
The Ohio State University

John Reagan, MD 2014
Rhode Island Hospital

Justin Reitsma, PhD 2015
California Institute of Technology

Jessica Ridilla, PhD 2015
Brandeis University

Cory Rillahan, PhD 2015
Memorial Sloan Kettering Cancer Center

Prabha Sarangi, PhD 2016*
Dana-Farber Cancer Institute

Amir Schajnovitz, PhD 2015
President & Fellows of Harvard College

Claudio Scuoippo, PhD 2014
Columbia University Medical Center

Zhen Shen, PhD 2015
The Rockefeller University

Alan Shih, MD, PhD 2015
Memorial Sloan Kettering Cancer Center

Richelle Sopko, PhD 2013
Harvard Medical School

Jamshid Sorouri Khorashad, MD, PhD 2015
The University of Utah

Kendra Sweet, MD 2014²³
H. Lee Moffitt Cancer Center & Research Institute

Shih-Chieh Ti, PhD 2014
The Rockefeller University

Anastasia Tikhonova, PhD 2015
New York University School of Medicine

Zuzana Tothova, MD, PhD 2016*
Dana-Farber Cancer Institute

Gianluca Varetta, PhD 2014
Dana-Farber Cancer Institute

Isana Veksler-Lublinsky, PhD 2015
University of Massachusetts Medical School

Nathan Westcott, PhD 2014
The Rockefeller University

Bas Wouters, MD, PhD 2016*
Erasmus University Rotterdam

Heping Xu, PhD 2016*
Cincinnati Children's Research Foundation

Chao Yang, PhD 2016*
Icahn School of Medicine at Mount Sinai

Xiaodi Yu, PhD 2014
Boston Children's Hospital

Joshua Zeidner, MD 2015
The University of North Carolina at Chapel Hill

Haojian Zhang, PhD 2014
Dana-Farber Cancer Institute

Yu Zhang, PhD 2015
Boston Children's Hospital

Hufeng Zhou, PhD 2016*
Brigham and Women's Hospital

¹⁵ Dr. Jane Skok is funded in part by The Jim Jacobs Charitable Foundation.

¹⁶ Dr. Loren Walensky is funded in part by Hockey Fights Cancer.

¹⁷ Dr. Jing Zhang is funded in part by The Greater Milwaukee Foundation, Inc.

¹⁸ Dr. Tiffany Chang is funded in part by Cynthia Hinojosa and Sydney Tassin.

¹⁹ Dr. Cihangir Duy is The Jake Wetchler Foundation Fellow of LLS.

²⁰ Dr. Chen Fang is funded in part by the Melryder Foundation.

²¹ Dr. Charles Gawad is funded in part by the Rally Foundation for Childhood Cancer Research.

²² Dr. Sarwish Rafiq is The Jake Wetchler Foundation Fellow of LLS.

²³ Dr. Kendra Sweet is funded in part by Imagine a Cure for Leukemia.

* Newly awarded or renewed grants in fiscal year 2016

† This program is run in partnership with the Myeloproliferative Neoplasm Research Foundation (MPNRF)

RESEARCH GRANTS (CONTINUED)

TRANSLATIONAL RESEARCH PROGRAM

The Translational Research Program supports outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients' lives.

Iannis Aifantis, PhD 2016*
New York University
School of Medicine

Gheath Al-Atrash DO, PhD 2015
The University of Texas
MD Anderson Cancer Center

Caroline Arber, MD 2016*
Baylor College of Medicine

Mukta Arora, MD 2014
University of Minnesota,
Twin Cities

David Avigan, MD 2014
Beth Israel Deaconess
Medical Center

Robert Baiocchi, MD, PhD 2014
The Ohio State University

Ravi Bhatia, MD 2014
University of Alabama at
Birmingham

Bruce Blazar, MD 2015
University of Minnesota,
Twin Cities

Katherine Borden, PhD 2014
University of Montreal

Giulia Casorati, PhD 2016*
Fondazione Centro San Raffaele

Lucio Castilla, PhD 2015
University of Massachusetts
Medical School

Leandro Cerchietti, MD 2016*
Weill Cornell Medical College

Li Chai, MD 2016*
Brigham and Women's Hospital

Xiu-bao Chang, PhD 2014
Mayo Clinic

Jianjun Chen, PhD 2014
The University of Chicago

Tomasz Cierpicki, PhD 2014
University of Michigan

Curt Civin, MD 2014²⁴
University of Maryland, Baltimore

James Coghill, MD 2015
The University of North Carolina
at Chapel Hill

Seth Corey, MD 2014
Northwestern University

Chi Dang, MD, PhD 2014
University of Pennsylvania

Sandeep Dave, MD 2016*
Duke University Medical Center

Bimalangshu Dey, MD, PhD 2014
Massachusetts General Hospital

Elizabeth Eklund, MD 2014
Northwestern University

Rudi Fasan, PhD 2014
University of Rochester

Adolfo Ferrando, MD, PhD 2015
Columbia University
Medical Center

Maria Figueroa, MD 2014
Weill Cornell Medical College

Stephen Forman, MD 2014²⁵
Beckman Research Institute
of the City of Hope

Mark Frattini, MD, PhD 2015
Columbia University
Medical Center

Paul Frenette, MD 2015
Albert Einstein College of
Medicine of Yeshiva University

Karin Gaensler, MD 2014
University of California,
San Francisco

Patricia Gallagher, PhD 2014
Wake Forest University
Health Sciences

Stephen Gottschalk, MD 2016*
Baylor College of Medicine

Douglas Graham, MD, PhD 2016*
Emory University

Steven Grant, MD 2015²⁶
Virginia Commonwealth
University

Jolanta Grembecka, PhD 2016*
University of Michigan

H. Leighton Grimes, PhD 2013²⁷
Cincinnati Children's Hospital
Medical Center

Javeed Iqbal, PhD 2014
University of Nebraska
Medical Center

Richard Jones, MD 2015
Icahn School of Medicine
at Mount Sinai

Marina Konopleva, PhD 2016*
The University of Texas
MD Anderson Cancer Center

Andrew Kung, MD, PhD 2015
Columbia University
Medical Center

John Kuruvilla, MD 2013²⁸
University Health Network

Dean Lee, MD, PhD 2014
The University of Texas
MD Anderson Cancer Center

Ross Levine, MD 2013²⁹
Memorial Sloan Kettering
Cancer Center

Mignon Loh, MD 2015
University of California,
San Francisco

Thomas Loughran, MD 2014
University of Virginia

Ivan Maillard, MD 2015
University of Michigan

Matthew Matasar, MD 2014
Memorial Sloan Kettering
Cancer Center

William Matsui, MD 2016*
Icahn School of Medicine
at Mount Sinai

Ari Melnick, MD 2014
Weill Cornell Medical College

Constantine Mitsiades, MD,
PhD 2014
Dana-Farber Cancer Institute

Tarik Moroy, PhD 2015³⁰
Institut de Recherches
Cliniques de Montreal

Nikhil Munshi, MD 2016*
Dana-Farber Cancer Institute

Markus Muschen, MD, PhD 2014³¹
University of California,
San Francisco

Nicolas Nassar, PhD 2014
Cincinnati Children's Hospital
Medical Center

Antonio Palumbo, MD 2016*
Universita degli Studi di
Torino-Dipartimento di
Biotecnologie e Scienze
per la Salute

Christopher Park, MD, PhD 2014
Memorial Sloan Kettering
Cancer Center

Alessandra Pernis, MD 2014
Hospital for Special Surgery

Javier Pinilla, MD, PhD 2015³²
H. Lee Moffitt Cancer Center
& Research Institute

Karen Rabin, MD 2014
Baylor College of Medicine

Anjana Rao, PhD 2015
La Jolla Institute for Allergy
and Immunology

Feyruz Rassool, PhD 2016*
University of Maryland

Katy Rezvani, MD, PhD 2015
The University of Texas
MD Anderson Cancer Center

Alain Rook, MD 2016*
University of Pennsylvania

James Rubenstein, MD, PhD 2014
University of California,
San Francisco

Stefanie Sarantopoulos, MD,
PhD 2016*
Duke University Medical Center

Aaron Schimmer, PhD, MD,
FRCP 2015
University of Toronto

Matthew Shair, PhD 2014
Harvard Medical School

Ulrich Steidl, MD, PhD 2014
Albert Einstein College of
Medicine of Yeshiva University

Kris Thielemans, MD, PhD 2016*
Vrije Universiteit Brussel

Andrei Thomas-Tikhonenko,
PhD 2016*
The Children's Hospital
of Philadelphia

John Timmerman, MD 2014
University of California,
Los Angeles

Steven Treon, MD, PhD 2015
Dana-Farber Cancer Institute

Amit Verma MBBS 2016*
Albert Einstein College of
Medicine of Yeshiva University

David Wald, MD, PhD 2016*
Case Western Reserve University

Roland Walter, MD, PhD 2016*
Fred Hutchinson Cancer
Research Center

David Wiest, PhD 2014
Fox Chase Cancer Center

David Wu, MD, PhD 2014
University of Washington

B. Hilda Ye, PhD 2015
Albert Einstein College
of Medicine

Qing Yi, MD, PhD 2015
Cleveland Clinic Foundation

Johannes Zakrzewski, MD 2015
Memorial Sloan Kettering
Cancer Center

Chengcheng Zhang, PhD 2014
UT Southwestern Medical Center

²⁴Dr. Curt Civin is funded in part by Northrop Grumman.

²⁵Dr. Stephen Forman is funded in part by The Jim Jacobs Charitable Foundation.

²⁶Dr. Steven Grant is funded in part by the Breeden-Adams Foundation.

²⁷Dr. H. Leighton Grimes is funded in part by The Marge & Charles J. Schott Foundation and the Cincinnati Golfers for Charity.

²⁸Dr. John Kuruvilla is funded in part by Drive For a Cure.

²⁹Dr. Ross Levine is fully funded by The Norcross Foundation, Inc.

³⁰Dr. Tarik Moroy is fully funded by the Edward P. Evans Foundation.

³¹Dr. Markus Muschen is funded in part by an anonymous donor.

³²Dr. Javier Pinilla is funded in part by Imagine a Cure for Leukemia.

RESEARCH PORTFOLIOS

TRANSLATIONAL RESEARCH PROGRAM: RENEWAL

Stephen Ansell, MD, PhD 2016*³³
Mayo Clinic Rochester

Smita Bhatia, MD, MPH 2016*
The University of Alabama
at Birmingham

Katherine Borden, PhD 2015
University of Montreal

John Byrd, MD 2015³⁴
The Ohio State University

John Crispino, PhD 2015
Northwestern University

Ryan Wilcox, MD, PhD 2016*
University of Michigan

MPN CHALLENGE GRANTS†

Nadia Carlesso, MD, PhD 2016*
Indiana University School
of Medicine

Robert Kralovics, PhD 2016*
Center for Molecular Medicine
of the Austrian Academy
of Sciences

Zhijian Qian, PhD 2016*
University of Illinois at Chicago

Katya Ravid DSC, PhD 2016*
Boston University
School of Medicine

Brady Stein, MD 2016*
Northwestern University

Zhaohui Ye, PhD 2016*
Johns Hopkins University

Leonard Zon, MD 2016*
Boston Children's Hospital

SCREEN TO LEAD PROGRAM

Michael Deininger, MD, PhD 2014
The University of Utah

SPECIAL INITIATIVES

Ari Melnick, MD 2015³⁵
Weill Cornell Medical College

Igor Roninson, PhD 2016*
University of South Carolina

TRANSFORMING CURES INITIATIVE

John Crispino, PhD 2016*
Northwestern University

Phillip Koeffler, MD 2016*
Cedars-Sinai Medical Center

Raghuvver Mali, PhD 2016*
Indiana University-Purdue
University Indianapolis

Akiko Shimamura, MD, PhD 2016*
Boston Children's Hospital

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Accurate Diagnosis Project is funded in part by Nonnie Barbey and John Sullivan, John and Frances Beck Family Foundation, BD, Genentech and Robert Rosen.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Samantha and Timothy Durst and Anonymous.

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by The Hildegard D. Becher Foundation, Inc.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Stephen and Madeline Anbinder, Deborah and Randy Daniels, George L. Shields Foundation, Tom Hancock, the Lasser Next Generation Fund, Anonymous.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Abbeville Family Partnership, Charles Foundation, Rebecca Godchaux, Larry and Leslie Nance.

Follicular Lymphoma Research Portfolio is funded in part by Beth Salter.

The Harry T. Mangurian Jr. Foundation – Beat AML Project is funded in part by The Ahern Family, The Altschul Foundation, The Stephen Birnbaum Foundation, William Blum, Blumenfeld & Waterman LTN Team, Peter and Janice Brock, Frona Brown, Chideo, Michael and Liz Copley, Dr. Deirdre Cosby and Alisa Morgan, Kathryn Dent & John Tillman Charitable Fund, Judy Dudley, Pat and Allen Dzuris, Charles Engelhard Foundation, Lisa Gaeta, Arthur J. Gallagher Foundation, Allan and Sherri Goldman, David Graiss, Kathleen Helge, Gayle and Jeff Helman, Chris Hoffmann Memorial, Murray and Diana Johnson, For Julie Foundation, Neil and Emily Kishter, Thomas Koski, Kayleen Larson Legacy Foundation, Paul Leinwand, The Robert H. Lyon Leukemia Foundation, Cyde S. McGregor and Leann Pederson Pope, Caren McCormack, LLS Marketing Campaign, John Saunders – Muskin Family Foundation, Mike Ohana, Pamela B. Katten Memorial Leukemia Research Foundation, Russ Parker, Ed & H Pillsbury Foundation, Donald Porteous, Bonnie Magid Roditti, the Rogers Family Foundation, the ROMA Charitable Foundation, Joan and Paul Rubschlager, Mark and Jacqueline Shulman, Mona Carlton Stogner & Grey Stogner, Michael and Liz Sweeney, Anonymous.

Hodgkin Lymphoma Research Portfolio is funded in part by Baltimore Tour de Court – in Memory of Rachel Minkove and Seattle Genetics and Team Natasha.

Immunotherapy Research Portfolio is funded in part by Sammons Enterprises.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by Access Capital Foundation and The Shimkin Foundation.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Douglas Baughman, Lisa and Craig Hawkins, and Debbie and Danny McQuary.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by John Barbey, Jay and Susan Clark, Lois and Jerry Rosenblum, Eleanor Sullivan, John Sullivan, Mindy and Kirk Uhrlaub.

Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by A.C.E. Family Foundation, BEP Foundation, Bob and Diana Carter, Thomas and Agnes Carvel Foundation, Franklin American Mortgage Company, Samuel Freeman Charitable Trust, J.T. Tai Foundation, Team Bright Side, The Wawa Foundation.

Quality of Life Research Portfolio is funded in part by Escher Foundation, The Hamill Family Trust, and Hildegard D. Becher Foundation, Inc.

Targeted Therapies is funded in part by Claire Fair.

Therapy Acceleration Program is funded in part by Jean and C.E. Andrews, Dr. Evelyn Bata, George D. Baker, Valorie and Mel Booth, Joe and Cynthia Bruno, Cora and John H. Davis Foundation, James H. Davis, PhD, JD, Virginia Sheldon Jerome Foundation, F.M. Kirby Foundation, Neil and Emily Kishter, Suzanne and Al Lord, Sherry and Steve Mayer, The Melryder Foundation, Rick and Stacey Nadeau, Phase Foundation, Joel Plotkin, Lois and Jerry Rosenblum, William J. Shaw Family Foundation, The Shimkin Foundation, The Sleep Family.

³³ Dr. Stephen Ansell is funded in part by The Adami-Robertson Family.

³⁴ Dr. John Byrd is funded in part by Bill Cress/Felice Shapiro.

³⁵ Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

* Newly awarded or renewed grants in fiscal year 2016

† This program is run in partnership with the Myeloproliferative Neoplasm Research Foundation (MPNRF)

ENDOWMENT FUNDS

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation – Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund
Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund
The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund
The UFCW (Canada) Endowment Fund

PARTNERSHIPS

THERAPY ACCELERATION PROGRAM PARTNERSHIPS

Acetylon Pharmaceuticals, Inc.
Boston, MA
Affimed Therapeutics AG
Heidelberg, Germany
arGEN-X BV
Breda, Netherlands
BioTheryX, Inc.
Chappaqua, NY
Ivan Borrello, MD
Johns Hopkins University,
Sidney Kimmel Comprehensive
Cancer Center
Celator Pharmaceuticals, Inc.
Princeton, NJ
Asher Chanan-Khan, MD
Mayo Clinic Jacksonville
Christopher Cogle, MD
University of Florida
Constellation Pharmaceuticals, Inc.
Cambridge, MA
Curis, Inc.
Lexington, MA
Brian Druker, MD
Oregon Health & Science
University
Mark Frattini, MD, PhD
Memorial Sloan Kettering
Cancer Center
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Jolanta Grembecka, PhD
University of Michigan
Anand Jillella, MD
Emory University
Kite Pharma, Inc.
Santa Monica, CA

Holbrook Kohrt, MD, PhD
The Board of Trustees of the
Leland Stanford Junior University
The Learning Collaborative
Kansas City, KS
Ron Levy, MD
The Board of Trustees of the
Leland Stanford Junior University
OncoPep, Inc.
North Andover, MA
Daniel Pollyea, MD
University of Colorado
Yogen Saunthararajah, MD
Cleveland Clinic
Stemline Therapeutics, Inc.
New York, NY
Valor Biotherapeutics, LLC
Dallas, TX

ADVISORS

MEDICAL & SCIENTIFIC ADVISORS

Steven Rosen, MD, FACP
Beckman Research Institute
of City of Hope
Chair
Stephen Ansell, MD, PhD
Mayo Clinic
Ravi Bhatia, MD
The University of Alabama
at Birmingham
Alexandra Mayes Birnbaum
Peartree Communications, Inc.
James Bradner, MD
Dana-Farber Cancer Institute
Alan D'Andrea, MD
Dana-Farber Cancer Institute
Giulio Draetta, MD, PhD
The University of Texas
MD Anderson Cancer Center
Philip Frost, MD, PhD
Opko Health, Inc.
Larry Kwak, MD
Beckman Research Institute
of City of Hope
Michelle LeBeau, PhD
The University of Chicago
Ross Levine, MD
Memorial Sloan Kettering
Cancer Center
Jonathan Licht, MD
Northwestern University
Alan List, MD
H. Lee Moffitt Cancer Center
& Research Institute
Susan O'Brien, MD
University of California, Irvine
Franklin O. Smith, III, MD
Medpace

THERAPY ACCELERATION PROGRAM ADVISORS

Dana Callow, MBA
Boston Millennia Partners
Chair
James Bradner, MD
Dana-Farber Cancer Institute
Joseph Catino, PhD
Retired from Bayer
C. Casey Cunningham, MD
Santé Ventures
William Dalton, MD, PhD
M2Gen
Ian W. Flinn, MD, PhD
Tennessee Oncology
Jennifer Gordon, PhD, JD
Paul, Weiss, Rifkind, Wharton
& Garrison LLP
Ross Levine, MD
Memorial Sloan Kettering
Cancer Center
Vern Norviel, JD
Wilson, Sonsini Goodrich
& Rosati
Susan M. O'Brien, MD
University of California, Irvine
J. Fred Pritchard, PhD
Celerion

DONORS

The below listing is made up of individuals, foundations and corporations that generously supported LLS's mission during this fiscal year.

\$1,000,000 AND ABOVE (LEADERSHIP CIRCLE)

Barclays
The Beer Store
Bristol-Meyers Squibb Company (PS) (C)
Burlington
Celgene Corporation (PS) (PP) (C)
Genentech, Inc. (PS) (PP) (C)
Gilead Sciences, Inc. (PS) (C)
The Harry T. Mangurian, Jr. Foundation, Inc.*
Novartis Pharmaceuticals Corporation (PS) (C)
The Olive Garden Italian Restaurant
Onyx Pharmaceuticals, a Subsidiary of Amgen (PS) (C)
The Paul E. Singer Family Foundation*
Pharmacyclics/Janssen Pharmaceutical Companies (PS) (R) (C)
Takeda Pharmaceuticals USA, Inc. & Affiliates (PS) (C)
United Food and Commercial Workers International Union Canada/TUAC
United Food and Commercial Workers Union/UFCW

\$500,000 – \$999,999 (CHAMPION)

Kathryn and Rush Limbaugh
The Norcross Foundation, Inc. in Memory of Herrick F. Norcross, Jr. (Rick)*
PVH
Sarah Cannon Blood Cancer Network
Stiglitz/Lang Family Fund
Teva Pharmaceuticals (PS) (C)

\$250,000 – \$499,999 (VISIONARY)

BDO
Carter's Inc.
Elbit Systems of America
EY
Global Franchise Group
IHOP
Elizabeth and Charles Jacobs
Cristine and Timothy Lindenfelser*
PwC
Pfizer, Inc. (PS) (PP) (C)
Amanda and G. Brint Ryan
Salesforce.com
Silicon Valley Bank
Stater Bros. Charities
Kathryn and Leo Vecellio*
Walgreens
Wells Fargo

\$100,000 – \$249,999 (PATRON)

Alex and Ani
Alto- Shaam, Inc.
The Amgen Foundation
Arthur J. Gallagher Foundation
At Home
Baker Botts LLP
Dr. Evelyn Bata
BB&T Bank
The Blackstone Charitable Foundation
BMC
Boehringer Ingelheim (PS)
Booz Allen Hamilton
Peter and Janice Brock*
CA Technologies
Cancer Treatment Centers of America
Clyde S. McGregor & LeAnn Pederson Pope in Memory of Joan Knowing McGregor
David Yurman
Deloitte
Discount Tire Co.
F. M. Kirby Foundation
FIS Foundation
Fleming's Prime Steakhouse & Wine Bar
Florida Cancer Specialists & Research Institute

Ethel and Bernard Garil
GEICO
Global Traveler Magazine
GSP Transportation
Hayes Family Fund
HM Insurance Group
Hospira Foundation (PS)
Kat Hurd
John and Kristin Hyland
Incyte Corporation (PS)
Industrial Alliance Insurance and Financial Services
Neil and Emily Kishter
KPMG
Lighthouse Investment Partners, LLC
Paul Leinwand
Jackson Lewis
LLS New York City Chapter Board of Trustees
The Marge & Charles J. Schott Foundation*
Mercedes-Benz USA, LLC
Missouri Foundation for Health
Northern California Cure-a-Thon
Northrop Grumman
Pamela B. Katten Memorial Leukemia Research Foundation
PhRMA
Donald Porteous
Bonnie Magid Roditti
Nancy C. and Richard Rogers
Samuel Freeman Charitable Trust
Seattle Genetics
SMART Modular Technologies
Spectrum Pharmaceuticals, Inc. (PS)
Terumo BCT
Vistar
VITAS Innovative Hospice Care
Waddell & Reed
Western Reserve Restaurant Management Inc.
Anonymous (1)

\$50,000 – \$99,999 (INNOVATOR)

ABM Janitorial-Midwest
Allegheny Foundation
Allstate Insurance Company
Alon 7-Eleven
American Airlines

American Systems
Amgen
Jean and C.E. Andrews*
Bank of America Merrill Lynch
Nonnie and John Barbey
BaubleBar
Briggs Equipment
Jaime Burgess
Patrick Byrne
Jessica and Kirk Cassidy
Rita Cavanagh and Gerald Kafka
C.H. Robinson Worldwide, Inc.
C.J. Coakley Co., Inc.
CareFirst BlueCross BlueShield
The Charles Engelhard Foundation
The Charles T. Bauer Charitable Foundation
The Coleman Foundation, Inc.
Comcast Spotlight
Community Foundation Sonoma County
Community Health Charities
Dennis Crowley
Matthew Dorsey
Earl D. and Marian N. Olson Fund
Enmark Stations, Inc.
EZCorp
For Julie Foundation, Inc.
Kevin Fried
Garden City Turkey Trot
Dr. Frank and Dr. Jillian Glass
Lee Goodwin and Linda Schwartzstein*
Andy Gordon
The Hamill Family Trust
Hargrove
The Harry and Jeanette Weinberg Foundation, Inc.
Allan Holt
Infor
J & J Development
J & J Shared Services
The Jake Wetchler Foundation
Tony and Amie James
Jazz Pharmaceuticals (PS)
John and Frances Beck Family Foundation
John Kellenyi
K-Town Kickin for a Cure
Kolache Factory

Laborers' Charitable Foundation
Melissa Leatherbury
Lehigh Valley Restaurant Group/ Red Robin
Steven Lieblich
Lilly (PS) (C)
Lundbeck Canada Inc.
Mammel Foundation
Dee Dee McCarron
Kelly McGee
Merchandise Pickup Service, Inc.
The Merck Foundation
Metro Richelieu Inc.
New York Community Bancorp
Jeffrey J. Nielson and Jon W. Silcox
Northern California Organized Labor
Northwestern Mutual – Minneapolis
The Orokawa Foundation
Parents Against Leukemia
PRG
Troy Rice
Re-Remission for Ryan
Jerry and Lois Rosenblum
Salt River Pima-Maricopa Indian Community
Harvey and Yetta Saltzman
Sammons Enterprises, Inc.
Sarver Charitable Trust
Stephen A. Schwarzman
Scottsdale Healthcare
Sedano's Management, Inc.
Stephen Scherr
Dee Anna and Hubie Smith
Emily and Chad Stevens
Sysmex America, Inc.
Team Walkin' Row
Therakos
The Thomas J. Perkins and Gerd Perkins Foundation
Timex
Toll Brothers
Townstar
TRM Memorial Research Foundation
truenorth
UBS Financial Services, Inc.
University of California, Irvine
Vanderbilt Sigma Chi Fraternity
Walmart

The Victor E. and Caroline E. Schutte Foundation – 1959
The Walt Disney Company
Washingtonian Magazine
WAWA, Inc.
The Whitney Foundation
Richard G. Wilbur
Anonymous (5)

\$25,000 – \$49,999 (ADVOCATE)

3 Sisters Ranch
21st Century Fox
A.C.E. Family Foundation
ADP
Aetna
Stephen and Madeline Anbinder
Alverin M. Cornell Foundation
Ameren
American Family Care
Amgen Oncology
Annaly Capital Management
Anthem Blue Cross & Blue Shield
Aon Risk Solutions
ARAMARK
Assurant Specialty Property
Astellas Pharma US, Inc. (PP)
Axia Energy
Baker Tilly
Baltimore Tour de Court in Memory of Rachel Minkove
Baptist Health South Florida
Douglas H. Baughman
BBVA Compass
Beach Body LLC
Peggy Beckman
Benevity Community Impact Fund
James Bennett
Bert Smith & Co.

PHARMACEUTICAL FUNDING LEGEND

(PS) PATIENT SERVICES
(PP) PUBLIC POLICY
(R) RESEARCH
(C) CAMPAIGN

DONORS (CONTINUED)

Beyond The Rack	Francis Dorrity and Margaret McGee	Janssen	Phillips-Van Heusen Foundation Inc.	Ellen Weissberg	Anadarko Petroleum
BJC Healthcare	Marian Dozier	Jewish Community Foundation of Cherry Hill	Ping Y. Tai Foundation	WASH-FM	Ann Taylor
Black Dog Charity	Driscoll's	The Jim Jacobs Charitable Foundation	Joel Plotkin	Washington Business Journal	The Anne & Henry Zarrow Foundation
BMO Harris Bank	Samantha and Timothy Durst*	Steven and Ellen Jackson/ACI International	PNC Bank	Western Refining	Team Annie Rose Foundation
Bon Secours St. Francis Health System	The Edgar A. Thronson Foundation	Jimmy Pappas Memorial Shoot	Jenny Pruitt	Wet Willie's Management Corp.	Ariad Pharmaceuticals, Inc.
Mel and Valorie Booth*	Faulkner Subaru	Susan Karches	Quintiles, Inc.	William R. Rich Foundation	Artel LLC
Boscov's	FBR	K2 Intelligence, LLC	Rally Foundation for Childhood Cancer Research	Woodmont High School	AstraZeneca
Braman Honda	Financial Recovery Strategies, First Business Bank	Kaiser Permanente	Ray Catena Auto Group	WTOP Radio	Augusta Oncology Associates
Brayton Purcell, LLP	Florida Power & Light Company	Kent's Run	Regions Financial Corporation	Zappos.com	Auntie Lao's Fan Club
Morris and Pamela Brown	Flushing Bank	King & Spalding LLP	Resource America, Inc.	Anonymous (2)	Avalon Bay
Joe and Cynthia Bruno*	Fox5	The Kroger Foundation	Rhulen Rock Hill Run & Ramble	<u>\$10,000 - \$24,999 (GIVING CIRCLE)</u>	Avella Specialty Pharmacy
John Bryant	Franklin American Mortgage Company	Don C. & Diane S. Lake Family	Rierner & Braunstein LLP	7 Eleven, Inc.	Maria Avila
Cardinal Solutions	Furniture Fair	Leon Medical Centers	Robert A. Rosania	67 Whippany Constructor, LLC	Bacardi USA
The Caring Foundation	G&T Orthopaedics and Sports Medicine	Brian Levine	ROMA Charitable Foundation	225 Fourth LLC/ Orda Management Corp	Michaëlle and Brian Bahnsen
Carlos Batista Foundation	Generac Power Systems	Al and Suzanne Lord	RPA Advisors, LLC	1000 Club to Benefit Cancer, Inc.	Bailey's Cancer Busters
Carlson Family Foundation, Inc.	General Dynamics Information Technology	The Lotz Family Foundation	Jeff and Pat Sachs*	Abacus Group, LLC	Paul Baits
Mona Carlton and Grey Stogner	John George	Lunardi's Supermarket Inc.	Jeffrey D. Sachs	Abacus Technical Services, LLC	Jocelyn Ball
Michael W. Carraway	Gila River Casinos	Macquarie	SanDisk	ABC 7/WJLA-TV	Banner MD Anderson Cancer Center
CBRE	Allan and Sherri Goldman	Manatt, Phelps & Phillips, LLP	Scott Savacool	Abramson Cancer Center	Banner University Medical Center
CBRE - New England	David Grais	Marsh Supermarkets, Inc. (Corp)	Helena Scott	Access Capital Foundation	Mike and Joyce Barker
CFACQ	Great American Insurance Group	Roxanne and Rocco Martino	Rhonda and Bob Silver	Ace Parking*	The Baratta Family Fund
Chambers Family Foundation	HCA Foundation	MAXIMUS Foundation	Roger Staubach	ACHS Insurance Company	The Barbara and William Rosenthal Family Foundation
The Charter Foundation	Sera Hernandez	Mayo Clinic	Sephora	Acosta	Bartlett Cocke General Contractors
Chiaramonte Construction Company	Andrew Herzig	The McLelland Family Foundation	The Shimkin Foundation	The Adriance-Finch Fund	BASF The Chemical Company
Cincinnati Golfers for Charity	Hewlett-Packard	MB Financial	The Smashburger Servicing Company LLC	Ann Adams	Lee Bates
CliftonLarsonAllen	AI G. Hill, Jr.	MedImmune, LLC	Solutionreach, Inc.	Adler Realty	Beacon Capital Partners
Comcast	Highland Park Village	Merck	St. Joseph's/Candler	afd Contract Furniture Inc.	Beckman Coulter Foundation
Comedy Central	Hildegard D. Becher Foundation Inc.	Michael C. Fina	Stephen Birnbaum Foundation	Agero Administrative Service Corp.	Becky and Dana Callow Family
Commerce Bank	Hoffman-La Roche Limited	Miles & Stockbridge	Merck	Agios Pharmaceuticals	Ben Carter Enterprises
Communities Foundation of Texas	Honored Hero Run	Morgan Stanley	Merck	Ahern Family	The Ben May Charitable Trust
Dr. Deirdre Cosby and Alisa Morgan	Houlihan Lawrence Real Estate	The National Bank Of Georgia	Merck	Aider Company Limited	Bender Foundation
The Cottrell Foundation	In Memory of Henry "Butchie" Hubschman	New York Community Bank	Sunesis Pharmaceuticals, Inc.	Air Products	Jorge Benitez
Crane Fund for Widows and Children	Sharron Hunt	North Bay Cancer Alliance	Vivain Talavera	Akin Gump Strauss Hauer & Feld LLP	Les Bentley
Dana-Farber Cancer Institute	ICAP Services North America LLC	Norton Rose Fulbright	Tappan Zee Constructors, LLC	Albert and Elaine Borchard Foundation	The BEP Foundation
Danford Foundation	Independent Health	NPL Construction Company	TD Bank	Bergan-Henry Associates	The Berghoef/Boyle Foundation
David M. Polen Retirement Plan Trust	Industrial Alliance	Lynne and Greg O'Brien	Terranea Resort	Albrecht Family Foundation	Johanna Berkman and Manny Weintraub
Diamond Wireless	Infinity Pharmaceuticals PS	Offshore Sailing School	Tigerfight Foundation	Alliance Data	Berkshire Bank
DiBella's Old Fashioned Submarines	Insulators and Allied Workers International	The Offerdinger Family	Judy and Michael H. Thomas	Allianz Asset Management	The Bernal T. Chomeau Private Foundation
Roland Dickison	Investors Group Financial Services Inc.	OneSource Distributors	Tucker Holmes, P.C.	Allmond & Company, LLC	The Bernard McDonough Foundation
Digitas Health LifeBrands	Hamilton E. James and Amie James	Patrick Park	UFCW Local 99	The Altschul Foundation	Peter and Barbara Bernick
DLA Piper LLP		Paul & Joan Rubschlagher Foundation	Ultimate Software	American Punjabi Charity Golf Association	Robert Berry
The Donald J. Trump Foundation, Inc.		Peoples Natural Gas	UPMC	American CentFury Investments	Beta Engineering
		PEPCO	Valenti Mid-Atlantic Management, LLC	American Direct Marketing Resources LLC	Walt and Teri Bettinger
		PFG / Vistar	Valero Energy Foundation	American Electric Power	
		PGT Trucking, Pat Gallagher	Vinson & Elkins LLP	American Expediting Company	
			Virginia Sheldon Jerome Foundation		
			Seth Vivek		
			The W. O'Neil Foundation		
			Scott Ward		

DONORS (CONTINUED)

Walt and Teri Bettinger	Campbell & Brannon, LLC	Color Me Rad	Dechert LLP	Enterprise Holdings, Inc.	Fourteen Foods
BIO	CancerCare, Inc. (PS)	Comcast NBCUniversal	Ellen DeChristopher	Enterprise Rent-A-Car	Fox Group Matching Gifts Program
Bisnow	Capital One Bank	Community Blood Center/Community Tissue Services	Detek	Entertainment Software Association	FPL Energy Power Marketing, Inc.
Blake Real Estate	Capitol Hospitality, LLC	Community Medical Centers	Joseph DeSabia	Epic	Frankel Enterprises
Bloomberg LP	Capstone Advisory Group, LLC	CONCACAF	Deutsche Bank	Equestrian Sports	Frazier & Deeter, LLC
Blue Cross & Blue Shield of Mississippi	Carahsoft Technology	Robyn and Don Conlon	Dickinson Fleet Services	The Escher Foundation	Fred Smith Plumbing & Heating Co.
Blumenfeld Development Group	Carbide Concepts Co. LLP	Contemporary Electric Services, Inc.	Dillon Cameron	ESPN980	Fresno/Clovis New Car Dealers Association
Brad Blumenfeld	Caribbean Property Group	Charles Cooper	DIRECTV	Estadil Secured	Freson Bros.
Susan Blumenfeld	Carnival Cruise	Liz and Michael Copley	Dittmar Company	Esther Mendez Foundation	Elyssa and William Friedland
BMHC – BMC West Selectbuild	Carol Lavin Bernick Family Foundation	Cora & John H. Davis Foundation	Sean DiTullio	Express Scripts	Frieze Harley – Davidson Sales Inc.
BNY Mellon Match	Carolinas HealthCare System	Cordia Partners	DLE Equipment	Claire Fair*	FTI Consulting
Steven Boal	Michael Carr	The Cornell/Nicholson Team at UBS	Dominion foundation	Fairmont San Francisco	Fund a Cure
Bobby & Steve's Auto World Youth Foundation	Donald J. Carter	Debra and Joseph Corrado	Domino's	Fairmont San Jose	Danny and Julie Funkhouser
Bocina Homes	CBIZ MHM, LLC	County of San Diego – Neighborhood Reinvestment Program	Don Duet	Fairmont Sonoma Mission Inn	FXExpress Publications, Inc.
Bognar & Company	Celator Pharmaceuticals	Courtney Knight Gaines Foundation	Paul Dorman	Faisal Rehman Medicine Professional (C)	GAI Consultants, Inc.
Boies, Schiller & Flexner, LLP	Centennial Technologies	Cowen Group, Inc.	Dr. Gerald and Paula McNichols Family Foundation	Edward Falk	Galen College of Nursing
Herman and Emmie Bolden	Centimark	Cox Family of Brownlee, SK Foundation	Tricia and Joel Drake	FALL Classic	Garage Isla Verde
Boston Bruins Foundation, Inc.	Century Elevator	Crane Co.	DreamWorks Animation	Shawn and Neda Fanan	The Gary and Pennie Abramson Charitable Foundation
Bowie Resources, LLC	Cerner Corporation	Credit Suisse	Dubose & Dorothy Heyward Memorial Fund	FarmerMac	Cynthia A. Gasztonyi
John Boyle	CertaPro	Crop Production Services – Dean Albrecht	Tom Dunham	Farmers 21st Century Insurance	Cindy and Brian Gavin
Brandywine Realty Trust	Chan Soon-Shiong Family Foundation	Cross Country Consulting	Dylan Perry Memorial Golf Tournament	Gregg Fasbinder	GE Capital Foundation
Brass Craft	Charity Buzz	CruCon Cruise	EagleBank	FATA Hunter	GE Johnson Construction Company
Breeden-Adams Foundation	Charles Foundation and Becky Godchaux	Cruise Industry Charitable Foundation	The Earl and Brenda Shapiro Foundation	Faulkner Honda	Geico Philanthropic Foundation
Brewers of Indiana Guild, Inc.	Chase Family Foundation	CSL Behring Canada Inc.	Eckert Seamans Cherin & Mellott, LLC	Suzanne Fedder	General Dynamics Advanced Information Systems
Faye Briggs	Mark S. Chehi	Cubist Pharmaceuticals (C)	Ed & H. Pillsbury Foundation	Edward Fein	George & Mary Josephine Hamman Foundation
Robert Brower	Chesney Miles Charitable Fund	Timothy Curt	Edith M. Schweckendieck Trusts	Ferrari Club of America	The George F. And Myra Shaskan Foundation, Inc.
The Brown Family	Chick-fil-A	Cushman & Wakefield	EFESTE Winery	FG Services	George L. Shields Foundation, Inc.
Brown & Gould	Chideo	CW & Dorothy G. Love Foundation	EJF Capital LLC	FIKE Corporation	George Mason Mortgage
Frona Brown	Childrens Hospital & Medical Center	Ashley Dabbieri	EKS&H	H. Bruce Finch	Georgia Drywall, Inc.
Howard Brown	Deborah Christine	Dallas Auction Gallery	El Scorcho	First American Title Insurance Company	
Bruce Cohen Memorial Cancer Foundation	Christy Houston Foundation	Danaher Corporation	Elap Services	First NBC Bank	
The Bruce and Pricilla Hutchins Family	Justine, Pauline, Aidan and Natalie Chueh	Thuy and Mitch Dancik	Elizabeth Gracie/O'Keefe Lyons and Hynes	First Niagara Bank	
The Bruning Foundation	Church & Dwight	Deborah and Randy Daniels	Elks of Los Angeles Foundation	First Service Credit Union	
BTIG, LLC	CIESCO Inc.	Dan's Supreme Super Markets	Ellis & Ellis	Michael Fisher	
Buchanan Ingersoll & Rooney PC	CIGNA Foundation	John Dauer	EMC	Stephen Fitzpatrick	
Jeff, Carol and Rebecca Burch	Circle City Foundation	Donald W. Davis	Scott Emerson/The Emerson Group	Bruce Fletcher	
Burgerfi International	Cindy Citrone	James H. Davis, PhD, JD	The Employees of Maple Lodge Farms	FMC Corporation	
Margot Burgwyn	Clark Construction Group, LLC	Adrian De Brasi	EN Engineering	Foley & Lardner	
Burns & McDonnell	Elizabeth Clark	The de Moya Group Inc.	Energy Future Holdings	Ford Motor Company	
Butler Family Foundation	Clune Construction Company	Deans Knight Capital Management Ltd.	The Enrichment Foundation	Forest County Potawatomi Community	
Jennifer and Jeff Butler	Cobalt Talon		Entergy	David Forkey	
C. Jay Moorhead Foundation	Chris Coffin		Enterprise Holdings Foundation	Fortune Creation Company Limited	
Mary Cahill	The Cobb Foundation			Colleen Foster	
California Community Foundation Endowment Account	CohnReznick			Shannon and Justin Foster	
Cambria and Brian Reinsborough					

PHARMACEUTICAL FUNDING LEGEND

- (PS) PATIENT SERVICES
- (PP) PUBLIC POLICY
- (R) RESEARCH
- (C) CAMPAIGN

DONORS (CONTINUED)

Foundation	HireStrategy	Jane and Frances Stein Foundation	Korn Ferry	Luppe & Paula Luppen Family Foundation	Melryder Foundation
GetWellNetwork, Inc.	HITT Contracting, Inc.	Janssen Ortho LLC	Thomas Koski	M&T Bank	Otilia Melwani
Christos and Patricia Giannoulis	Rick Hoagland	Brian Jaramillo	Josh Kosnick	Mabee/Gumpert Philanthropic Fund	Memorial Health
Giant Food	Hogan Lovells Move	Jarden Westchester Tri	Charles F. Kriser	Matching Gifts	Memorial Sloan Kettering Cancer Center
Giant Tiger Stores Limited	Daniel Hood	Jared Coones Pumpkin Run	Kritchman Family Foundation	Tom Macek	Mendieta Alejandro Mendieta
Peter and Ann Gilbert	Albert Hopkins	JB Fuqua Foundation, Inc.	Kroger Community Rewards	Darren Machule	Mercy Health
Jill Gillette	Horizon Beverage Company, Inc.	JDP Mechanical Inc.	Jules and Lynn Kroll	Mack Madness, Inc.	Meringoff Family Foundation Inc.
Global Prairie	HOT 99.5	Jim Koons Automotive	The Kroll Family Foundation	Macy's	Merrill Lynch
GM-AC	Howard Family Foundation	The Jim Quay Memorial Fund	KST Data, Inc.	Macy's/Bloomingtondale's	Messer
The Gold Law Firm	Robert Howe	Joan C. Ray Charitable Foundation	KU School of Pharmacy Student Organizations	Magnolia Foundation	Elizabeth Meyer
Goldman Sachs	Hoxworth Blood Center	The John M. and Sally B. Thornton Foundation	The Lab World Group LLC	Magnum Power Products LLC	Michael & Son Services, Inc.
Brad Goldstein & Lauren Clymer	Tam and Dave Hubler	John T. Gorman Foundation	David Lacey	Robert Maher	The Michael Treinen Foundation
Peter D. and Catherine D. Gordon	Huffington Foundation	The John Simpson Memorial Golf Outing	Ladish Co. Foundation	Major Hyundai	Microsoft
Gosling's Rum	Hunter's Green Country Club	John Theurer Cancer Center	Michael Ladra	Malacos Properties, LTD	Microsoft Matching Gifts Program – NTX
Grainger	William Huntress	Johnson & Johnson Suncoast	Diane Lake	Mansfield Jackie Mansfield	Mike's Carwash
The Grainger Foundation	Huntsman LLC	Murray and Diana Johnson	John and Faye Lamb	Marble Slab Creamery	Millisor Family Foundation
Grand Finale Auction	Hy Vee, Inc.	Duane Johnston	Joni and Dave Lang	Margaret and Donald Austin Family Foundation	Mingledorff's Inc.
Grange Insurance Companies	IBC Bank	Joseph R. Daly Foundation	Lasser Next Generation Fund	Mariner Real Estate Management, LLC	Minneapolis Jewish Federation
Jonathan Gray	IBERIABANK	Kent Joshi	Latham & Watkins LLP	Marylou's Coffee	Mitsubishi Hitachi Power Systems
Gray Line of San Francisco	Ignition Footwear Company	Patrick Joyce	The LaVerna Hahn Charitable Trust	The Marksmen Company	Alan Mittleman
Greater Kansas City Community Foundation	Ilse Nelson Fund at New York Community Trust	The June and Cecil McDole Charitable Fund	William Lawlor	Mashkin Foundation	MMG Equity Partners
Greehey Family Foundation	IMS Health	JP Morgan Chase	Ralph Lawson	Massapequa Turkey Trot	Moffitt Cancer Center
Greenberg Traurig	Independence Blue Cross	Susan and Daniel G. Kane	Shane Lea	Massapequa Youth Lacrosse Club	Momentum Microsystems, Inc.
Hugo Gutierrez, Jr.	Indianapolis Indians	Kansas City Chiefs/Hunt Family Foundation	Michael Lebrun	Michael Maser	Thomas W. Moore
GZ Total Control, Inc.	Infinity Pharmaceuticals, Inc.	Raj and Vy Kapoor	Brian Lee	Kim and Matthew Mausser	Pat Moran
Hadden Landscape, Inc.	InfoReliance Corporation	Karing For Karley	Left Hand Brewing Company	Steve and Sherry Mayer*	Morgan Stanley
Cory and Jennifer Hall	Ingersoll Rand	In Memory of Betty Karpinski	Leland Morris Family Foundation, Inc.	Mayo Clinic Scottsdale	Global Impact Funding Trust
Leonard Halpern	InquisIT, LLC	Kasasa by BancVue	Leon S. Peters Foundation	Mays Family Foundation	Morgan, Lewis & Bockius LLP
Sheryl Hambidge	Insulators International Health Hazard Fund	Kathryn Dent and John L. Tillman Charitable Fund	Deborah Leone	MB Financial Bank	MorganFranklin Consulting
The Handlery Foundation	INTEC Group, Inc.	Stacey and David Kaufman	Leukemia 24/7	Mary E. McCaul	Morley – Metro Detroit
Robin Harman	Intel Security	Michael Keating	Levin Family Foundation	Caren McCormack	Phillip Moy
The Hartley Company	International Society, Herme deWyman Miro, President	KentuckyOne Health	Mary Whelan Levine	McCownGordon Construction	George Moynihan
The Harvey E. Najim Family Foundation	Interplanetary Inc.	The Kerins Family	Mary and Lawrence Liebscher	McDermott Will & Emery	MSC Industrial Supply Co.
Harv's Car Wash	Investors Group Financial Services	Kiewit Companies Foundation	Connie Lindsey	The McLaughlin Family	Gail Munzing
Diana Haverstick	ISC Sales LLC	Kilroy's Indy LLC	The Lipman Family	William McNitt	Tim Munzing
Lisa and Craig Hawkins	David and Jill Israel/Sessions, Fishman, Nathan & Israel, LLC	King Business Interiors	James Lippman	Debbie and Danny McQuary	Kevin and Mary Murphy
Karren Hays	Ivie and Associates	The Kirlin Group	LISI	Medavie Blue Cross	Murray Hill Properties
HBS MNA 2015 Section A	J.T. Tai & Co Foundation, Inc.	Larry and Kim Kittoe	Kim and James R. Lites	MediCom Worldwide (PS)	MUY Brands
Mark Heese	Jack Henry & Associates	Chuck Kiven	Little Treasures Inc.	Medidata	Rick and Stacey Nadeau*
John Heimann	David Jackson	Diana Knifer	Brian Littleton	Megan's Wings Inc.	Janet Nakushian
Kathleen Helge	The James Cancer Hospital/Wexner Medical Center at The Ohio State University	Knowledge Services	LMI	Sanjay Mehrotra	Names Family Foundation
The Helis Foundation	Foundation	Vickie Kontos	Lockheed Martin		Larry and Leslie Nance
Heritage Title Company of Austin, Inc.			Lord & Taylor		NARS
Rob Heyvaert			Hogan Lovells		National Association of Broadcasters
Marcy and Donnie Hill			Lukens Fund		National Neuromonitoring
Richard Hirayama					National Rural Utilities Cooperative Finance Corporation

DONORS (CONTINUED)

National Neuromonitoring	Lauren Pearson	Raynier Institute & Foundation	SALLY Games	Siteman Cancer Center	Karla Sustaita
National Rural Utilities	Peck Madigan Jones & Stewart, Inc.	RBC Capital Markets	Salomon William R. Salomon	Skadden Arps Slate Meagher & Flom LLP	Suzu, Nancy, Carol Minkoff Charitable Fund
Cooperative Finance Corporation	Pennant Foods Corporation	RBW Logistics	Sal's Mexican Restaurant	The Sleep Family	Mr. and Mrs. Jack Swan
Nationwide Children's Hospital	DBA Wendy's	Real Estate One Charitable Foundation	Beth Salter	Smigel, Anderson & Sacks	Michael B. Sweeney
Naturipe Berry Growers, Inc.	Mark and Mary Pennington	Reece Holbrook Win Anyway Foundation Inc.	Irvin Saltzman	Phyllis and Douglas A. Smith	Michael Sweig
Navarro Discount Pharmacy	Performance Automotive Network	Mark Regante	The Sam J. Frankino Foundation	Smith Family Fund	Joseph Tang
Nestle Purina Pet Care Company	Performance Truck Sales, Inc.	Reliant, an NRG Company	Samuel C. Cantor Charitable Trust	Jill Smith	Cynthia and Sidney Tassin
NetSuite	PerkinElmer Foundation	Richard M. Rendina	San Diego Sign Company	Patricia Snyder	Tauber Oil Company
The Netter Foundation	Perkins + Will	Republic National Distributing Company	Sandlapper Capital Investments	So Long to Leukemia	Team Chad
New York Life	Jon Perkins	James Resnick	John Saunders	South Texas Pathology Associates	Teamsters Local Union No. 25, Charlestown, MA
Bonni and Kenneth Newton	Perry Homes	Rex Healthcare	Sausalito Construction, Inc.	Southeast Food Services Company, LLC dba Wendy's	Tee Off Against Cancer
Andrew Nibley	Peter & Joanne Brown Foundation	Nina Richardson	Savills Studley, Inc.	Southeast Nebraska Cancer Center	Ted Britt Ford
Nidec Motor Corporation	Sheldon and Donita Petersen	Rick Richman	Robert & Adele Schiff Family Foundation	Southwestern Energy Co.	Tektronix
NOCO Energy Corp.	PGA TOUR SuperStore	Richmond Jewish Foundation	Kenneth L. Schlaudt	Stephen and Bonnie Spiegle	TELUS Community Affairs
Guy P. Nohra	Amber Tuyen Pham	Rick Case Enterprises, Inc.	Jan Schoenbauer	Spirit Extreme	Teneo Strategy LLC
North Sails	Phase Foundation	Cynthia and Steven Rigby	Schwab Charitable Fund	Mark and Carol Spisak	Terumo BCT
North Shore – LIJ	Tom Philbrick, MD	Suhail Rizvi and Patti Jean Blanchard	Harvey M. Schwartz	H. Mark Sponseller	Texas Children's Hospital
Norton Healthcare	The Phyllis M. Coors Foundation	RKH Properties	Scott Schweighauser	David and Justine Springberg	Texas Instruments, Inc.
Nova Genesis Intl Co Ltd	Sarah Pietrafesa	RNDC South Carolina LLC	ScotiaBank	Springer Services, Inc.	Texas Oncology
Novak Charitable Trust	Pilot Flying J	Road ID	Sears Holding Management Company	SRA International	Thomas and Agnes Carvel Foundation
NYSUT	Plato's Closet/Clothes Mentor/ Once Upon A Child	Robert A. and Kathey K. Anderson Foundation	Security Service Federal Credit Union	St. David's South Austin Medical Center	Thompson Coburn
Amanda Ober	Polk Brothers Foundation	Robert H. Lyon Leukemia Foundation	Sempra Energy Foundation	John Stafford	Thomas Jefferson University Hospital
Janice Obre	Polo Ralph Lauren Foundation	Robert Half International	Sennebogen LLC	Starkey Mortgage	Thompson Habib & Denison Inc.
Morgan O'Brien	Jim and Kathy Polsinelli	Robinson & Cole	Serpentini Chevrolet Inc.	Stater Brothers	Tishman Construction
Ockham Development Group	The Portmann Family Charitable Fund	Ruth E. Robinson	Severn Mechanical & Capital Drywall	Phil Steel	Tishman Speyer
Old Mutual Asset Management Charitable Foundation	PotashCorp	Rock Spring Contracting, LLC	Carl Sewell	Kathleen and James Stengel	Title Associates
Raphael Oliver	Powell Industries	Roderick S, Flossie R, & Helen M Galloway Foundation, Inc.	Shade Tree Services Co.	Sterling National Bank	TJX Foundation, Inc.
Walter Oliver	Pranger Family Foundation	Leah and Greg Rodgers	Jerry Shae	Stern Family Philanthropic Foundation	Robert Tomsich
Doug and Margit Olson	Presidential Detailing	Rogers Family Foundation	John Shaffer	Sterne, Kessler, Goldstein & Fox	Towers Watson
Pam Olson	Presidio	Greg and Mishel Rohl	Felice Shapiro	The Steven M. Perez Foundation	Toys R Us Children's Fund, INC.
The Omer Foundation	Lee and Amy Pressler	RoMa Jewelry, Inc.	Share the Wealth, Subaru	Diana and Todd Stiefel	TPAC Underwriters Inc.
Oncology Hematology Care, Inc.	Sheldon Pressler	Philip Romano	Sherrard Kuzz LLP	Stinson Leonard Street, LLP	Transwestern
Onyx Equities, LLC	Price Chopper Supermarkets	Ropes & Gray	Mike Shihad	Stoke, Inc.	TRIB Western Media
Oracle	Donald Proctor	Robert Rosen	The Shin Foundation	Stone Harbor Investment Partners LP	Trinity Industries Inc.
Peter O'Sullivan	Property Market Group	RPM Pizza (Dominos Pizza)	Shulman, Rogers, Gandal, Pordy & Ecker, P.A.	Stonebridge Companies	Trion Group, Inc.
Oxford Development Company	Prothema Biosciences, Inc.	Paul and Joan Rubschlagher	Sidley Austin LLP	Stream Energy	
Pacific Union Int'l. Inc.	Provision Health Alliance	Run Project	The Sidney, Milton and Leoma Simon Foundation	Subaru of America Inc.	
Ron Packouz	PSAV Presentation Services	SAFE Federal Credit Union	Sigma Phi Epsilon/Drake	Sullivan & Cromwell LLP	
Yolanda Padilla	PSEG	Safeway Inc.	Silicon Valley Community Foundation	Catherine Sullivan	
James and Gail Palmer	Quanta Services Management, LP	SAIC	Gilbert Simonetti III	Patrick and Pam Sullivan	
Palo Alto Medical Foundation/Sutter Health	Cary Queen	Sailing World	Michael Simpson	Summit Mortgage Corporation	
Papa John's	Rahr Malting Co.	John and Lauren Salata	Aviva and Peter Sisitsky	SunTrust Bank	
PAR Electrical Contractors, Inc.	The Randy and Deborah Daniel Family Charitable Foundation				
Park Manor of The Woodlands	The Raymond & Rita Foos Family Charitable Foundation				
Park Place Motorcars	Richard Ramsden				
PathGroup, Inc.					
Peake BMW					

PHARMACEUTICAL FUNDING LEGEND

-  PATIENT SERVICES
-  PUBLIC POLICY
-  RESEARCH
-  CAMPAIGN

DONORS (CONTINUED)

Angela and Gary Trovato
True North Family Foundation
Truitt Foundation
Trust Company of the South
Eddy Tsang
Turner Foundation Inc.
Renee and Larry Twersky
U.S. Chamber of Commerce
U.S. Steel
Mindy and Kirk Uhrlaub
Union Bank
Union First Market Bank
United Cancer Research Society, Inc.
The University of Kansas Cancer Center
University of Michigan
US Bank
USCW Local 1776
William E. and Jane Dorward Valentine
Natan Vaisman
Vanda Pharmaceuticals ©
VCU Medical Center
Venable LLP
Philip J. Venables
Venari Resources LLC
Verizon
Frank Vero
Vickar Foundation
Vidaris, Inc.
Visse Wedell
VITAS Healthcare Corporation
VJF Consulting, LLC
Madlyn Boccio Wagner
Walter J. and Betty C. Zable Foundation
The Warburg Pincus Society
James Wareham
Warner Pacific
Washington Executive Agency
Washington Gas
Waste Technology Services Inc.
WB Wood
WBIG
Kathie and Dave Weber
Henri and Marsha Wedell
David D. Weinstein
Mark G. Weinstein

Elaine Weisman
Weldon Service & Repair
WellHealth Quality Care
Wellpoint
Wells Fargo Private Bank
The Wendy's Company
Tim Werdel
The West Endowment
West Marine
Penny Westfall
Wicklund Warrior Fund
Mark and Jessie Wiktor
Curtis Wilker
WILL Grein
William G. Pomeroy Foundation
William J. Shaw Family Foundation
Williams & Connolly LLP
Greg and Wallace Williams
Willis Auto Campus
Willis Foundation
Winstead
Winston & Strawn LLP
Lynn and Mark Witmer
WIVB-TV, Channel 4/CW 23
WMZQ
Woman's Club of Hermosa Beach
World Bank Community Connection Fund
World Travel Holdings
World Wide Technology, Inc.
Marie Yanney
Eric, Tamara, and Nicholas Yollick
Adelaide W. Zabriskie
Lynne Zaccaria
Zaxby's
Cathy and Scott Zeilinger
Zuehl Family Fundraiser Supported by the Roaming Skullz
Joseph Zvesper
Anonymous (18)

TOP CAMPAIGN FUNDRAISERS

Schools that have raised more than \$25,000, Individuals who have raised more than \$50,000 or company/teams that have raised more than \$100,000 to support LLS's mission.

Guy Adami
Margaret and Chuck Aitken
Dean Albrecht
Alex and Ani
Helen Anbinder
Michael Anderson
Suzanne Anderson
Dr. Babis Andreadis
Russ Armstrong
At Home
Trey Axe
Sam Azar
Lindsey Bailer
Bailey's Cancer Busters
Emily Baird
Baker Botts LLP
Barclay Bishop and Team Barclay's Believers
Barclays
Carole Barita
D. Mark Barnhart
Marianna Barringer
BDO
Sarah Bender
Shannon Wolfson Bentle
Bill Rawlings and Team
Someday is Today
Barclay Bishop
The Blackstone Group
BMC
Katy Dix Brahler
Carly Brasseaux
Brian Fuller and Team Full of Life
Molly Brickler
Morris Brown
Cole Bryan
Patrick Byrne
Burlington
Mai Caldwell
Cancer Treatment Centers of America
Robert "Spider" Cantley

David Carr
Michael Carraway
Mary Carrillo
James W. Carter, IV
Carter's Inc.
Angela Casale
Eva L. Casale
Jessica and Kirk Cassidy
Celgene Corporation
Neerja Chaudhry
Christbridge Academy
John Clamme
Tiffanie Clausewitz
Brandon Clay
Aimee Clinkenbeard
The Cohan Cup
Gary Cohen
Chris Colón
Dr. Alessandra Colon
Colton's Army
Colton and Case Matter
Brianna Conticelli
Bridget Cook
Gina Cook
Brett Cooper
Lisa Cooper
Marcus Corwin
Crenshaw Team
Grace Cruickshank
Tracy Cunningham
Fran D'Alessandro
Lauren Dallas
Timothy Daly
Capri D'Amario
Shannon Darnell
Ann Davis
Deloitte
Dr. Anthony DeLuise
Erika Dimson
Discount Tire
Disney Team MA Chapter
Mary Dixon
Matthew Dorsey
Abby Douglas and Julia Davis
Devan Driscoll-Roach
Audrey Duffey
Sarah Edwards
Dr. Babak Eghbalieh
Elbit Systems of America

EY
Michael Faurest
Cameron Fay & Team Ganbattel
Lauren Fernandez
Jen Fertenbaugh
Finish Line
Vincent Fiordilino
FIS
Liam Fitzgerald
Stephanie Flax
Jason Fleischert
Kelly Floyd
Michael Foster
Shannon Foster
Nelson M. Francis
Tracy Fritts
Brian Fuller
Grant. M. Gaines
Chris Gannon
Hillary Gelfman
Genentech/Biogen Idec
Dr. Todd Gersten
Anne Giglio
Gilead
Dr. Frank Glass
Duncan and Finn Glew
Global Franchise Group
Goldman Sachs
Lissa Goldsmith
Francisco Gonzalez
Sue Ellen Goss
Karen Grace
Kristin Guerra
Berenise Guerrero
Ozzie Guillen, Jr.
Wes Gullett
Vishal Gurbuxani
Brianna Haag
Philippe Haddad
Summer Hall
Claire Harmer
Tracy Harrison
Lee Haydu
Lisa Henderson
Vera Herbert
Heritage Trails Elementary
Katie Simmons Hickey
Sandy Hickey
John Hite

Elizabeth Hogan
Constance Howlett
Tommy Hughes
Kat Hurd
I Run With Coach Joe
IHOP
Megan Imbert
Diana Iorlano & "Team Lemonade"
Tamara Jack
Sean Jackson & "Never Give Up"
Matt Jeffrey
Adela Jimenez
Johnny & the SuperHeroes
Just Cure It
Julie Karg
Katie's Crew
Ali Kavianpour
Katie Kelly
Janet Kiburz
Porschla Kidd
Reece King
Kiven, Kotler, Lieberman, Fox, Goldschmidt & Kepes
Stacy Kornetzke
Josh Kosnick
KPMG
Niccole and Jeremy Kroll
Maverick Kuhn and Abby Fitzgerald
Dr. Martha Lacy
Dallas and Team The Dallas Darlins
Brenda D. Lavell
Melissa Leatherbury
Gary Leff
Quinten Lepak
Damione Lewis
Jackson Lewis
Bill Lia, Jr.
Nick Linca
Dr. Alexis Lipton
LLS National Office Greene Team
Sarah Lott
Molly Magnuson
Dawn Malacos
Peter and Gina Manos
Dr. Mark Marinella
Jeremy Matza
Lisa Maurer

DONORS (CONTINUED)

Dee Dee McCarron
Rumiko McCarthy
JT McFadden
Chris McFarland
Kelly McGee
Nicole McGlothlin
Jessica Meyer
George Meza
Dr. Adam Mezoff
Michael Carraway and
Team Carraway for a Cure!
Freddy Mistry
Kathy Moeder
Jessica Moore
Dana Moraci
Inez Moriarty
Blake Morris
Brint Morrow
Kyle Mostransky
Paul Mozzocci
Benyam Muluneh, PharmD
Casey Munck
Dina Murokh & Together To Cure
Craig Murray
Megan Murray
National Capital Area MWOY
Leadership Team
Amie Nemeck
Tiffany Nguyen; Erin Macbeth
Jeffrey J. Nielson
Lynne O'Brien
Dominick Oliviero
Osbourn Park High School
David Panico
Partners For A Cure
Dr. Anjan Patel
Mary Pennington
Pharmacyclics/Janssen
Alex Pinelo
John Pinkerton
Robby Poteat
Greg Poulos
Lee Pressler
Tim Price
PVH
PwC
Brittanne Hammond Quigley
Erin Ragsdale†
Rampart High School

Dr. Brion Randolph
Dr. Brion Randolph and
Team Heme
Scott Randolph
Randy & Kathy Reunion Tour
Dr. Arati V. Rao
Liz Rapp
Carol Rausch
Bill Rawlings
Re-Remission for Ryan
Rebecca Sterner and Team
The Rockin' Raisers
Rylan Reed
Mike Reynold
Troy Rice
Sara Richburg
Ride For Ron
Riders of the Storm
Mark Rodgers
Jennifer Rogers and Robert
Carlock
Kevin Rohalmin
Christi Rotterdam
Justin Royce
Josh Rubinstein
Salesforce.com
David Salinas
Sarah Cannon Blood Cancer
Network
Stephanie Sanders
SanDisk
Tim Sargent
Cody Scarboro
SCDS Wildcat Climbers
Aaron Schifrin
Tom Schmidt
Allison Schnall
Julie Schneider
Scott Schweighauser
Helena Scott
SDG&E / Sempra
Seattle Fire – Team Tristan Smith
Seattle Genetics
Dr. Sheila Shahabi
Martha Shaker
Kevin Shannahan
Leana Shefman
Dr. Shahzad Siddique
Jon Silcox

Megan Sierveld Simpson
Stephanie Simpson
Aviva Sisitsky
Chris Small
Denise Smith
Kiernan Smith
Luke K. Smith
Society Ties – NYC
Tony Sorrentino
Dr. David Stapor
Stater Bros. Charities
Thomas H. Steele
Amanda Steffy
Rebecca Sterner
Stewart School
Stratford School, Curtis Campus
Adam Sussman
Suzanne Anderson, MD and
Team Grateful Times Ten
Takeda Pharmaceuticals USA, Inc.
& Affiliates
Leslie Tatel
Team Answer for Cancer
Team Audrey
Team Bacon Bits
Team Believe
Team Blumenfeld & Waterman
Team CURE
Team Debba
Team Dennewitz
Team Diana
Team Driscoll's
Team EJ
Team Foundry/Anthony DeLuse
Team G.A.I.L.
Team Jordan: Doing it for Emily
Team Kim
Team Laubach
Team LOL
Team Medtronic
Team Murawski
Team Natasha
Team on Fire
Team Paolini
Team Princess Margo/Powered
by Kailie's Krew
Team Reinhardt
Team Sally
Team Town Star/Subway

Team Waddell & Reed/Ivy Funds
Teva Oncology
Elizabeth (Libba) Thompson
Maya Thukral
Paul Titterington
Sonia Toledo
Sarah Topy
Team Town Star/Subway
Kelly Treinen
Cindy Tripp
Brad Tucker
Turning 10
Katy Ursta
Megan Van Pelt
Monica Vasquez
Alexandra von Plato
Vistar
VITAS Innovative Hospice Care
Walgreens
Walt Whitman High School
Walter Johnson High School
Brian Ward
Jenna D. Wardle
The Warriors
Washington Gas
Brian Waterman
Watertown Middle School
Dan Waugh
Jason Weiner
Rob Welker
Wells Fargo
Ronald M. Wolf, DDS, MS
Shannon Wolfson
Finlay Woodruff
Amanda W. Yopp
Cynthia Yosha-Snyder
Benjamin Zangoglia

† National Man & Woman of the Year

LEGACY CIRCLE

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of \$10,000 or more were received this year.

Eli Bakshi
Mary Baumgardner
Norman and Betty Bertiaux*
Mary Ann Bland
Edith Blankenship*
Dorothy Booth*
Robert Borsch*
Erwin Brandt*
Susan Branson*
Mr. and Mrs. Peter Brock
Joanne Burgett*
Angeline Capperino*
Marjorai Carus*
Gertraude Coleman
Rodger and Lorie Coon*
Mildred Crespín-Croegaert*
Margaret DiDonato*
Julian Dodge*
Peggy and Margaret Dupaquier*
Chester Elkind*
Cynthia Fay*
Rosabelle Fetty*
Nellie Fishman*
John Frerkes*
Stella Frerkes*
Carole Gardner*
Ronald Theodore Gibson*
Joseph Gilbert*
Wesley Gladow*
Charles Godchaux
Becky Godchaux
Rebecca Grajewski*
Howard Grant*
Mildred Grossman*
Carolyn Hamilton*
Joanne Hastings*
Bernice Houlihan*
Miriam Kaplan*
Dr. Judith Karp and
Stanley Freedman
Ellen Kemper
Thomas Keys*
Evelyn Kilker*
Barbara Kirsh
Allen Klein*

Fred Kohler and Kuo-Jung Chang
Peter Landecker
Virgil Levi*
H. Eleanor Lodholz*
Jennifer McGuire
Helen Jean Melious*
Ernest Newman*
Michael Pechanach*
I. Edward Picker*
Siegfried and Pamela Pinchut*
Robert and Cheryl Post
Edna Raupp*
Jennifer Rodrigues
Florence Rubino*
Robert Ruhe
Anita Schlacht*
Juanita Joyce Scholpp*
Ethel Schwarzman*
Gail Secrist*
Bruno and Irma Selmi*
Gerogia Shank*
Elisabeth Situm*
Georgianna Slanski-Lee
David R. Smith
Sidney M. Steiger*
(in Memory of
Vivian Blumberg Steiger)
Judith Ann Stimson*
Lois Stockert*
William Stockert*
Bruce Swartz*
Lois Mary Elaine Teisciero*
Leila Valentine*
Bernard and Christa
VanderLinden*
William Vaughan*
Estella Ruth Watts*
Hannah Weiss*
Jill Westhead*
Lars and Carol Wigert*
Richard Woody
Stanley Zaring*
John and Mary Zick*
Rosalyn Zohn

Anonymous (7)

* Deceased

INDEPENDENT AUDITORS' REPORT

The Board of Directors

The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2015, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITORS' RESPONSIBILITY Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

OPINION In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2015, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

REPORT ON SUMMARIZED COMPARATIVE INFORMATION We have previously audited LLS's consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated October 15, 2014. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2014 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

October 21, 2015

CONSOLIDATED BALANCE SHEET

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts at June 30, 2014) (In thousands)

	2015	2014
Assets		
Cash and cash equivalents (note 3)	\$ 52,897	28,771
Prepaid expenses and other assets	6,049	5,362
Legacies and contributions receivable, net (note 5)	8,989	9,113
Investments (note 3)	137,941	188,885
Fixed assets, net (note 7)	<u>14,826</u>	<u>16,604</u>
Total assets	<u>\$ 220,702</u>	<u>248,735</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 18,416	20,685
Deferred revenue (note 6)	17,802	26,745
Awards and grants payable (note 2)	69,335	84,201
Co-Pay assistance payable (note 2)	<u>14,465</u>	<u>16,698</u>
Total liabilities	<u>120,018</u>	<u>148,329</u>
Commitments and contingencies (notes 2 and 9)		
Net assets (note 4):		
Unrestricted	72,848	68,842
Temporarily restricted	24,146	27,989
Permanently restricted	<u>3,690</u>	<u>3,575</u>
Total net assets	<u>100,684</u>	<u>100,406</u>
Total liabilities and net assets	<u>\$ 220,702</u>	<u>248,735</u>

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF ACTIVITIES

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with summarized totals for the year ended June 30, 2014) (In thousands)

	Unrestricted	Temporarily restricted	Permanently restricted	Total	
				2015	2014
Operating Revenue					
Campaign contributions	\$ 236,171	23,258	—	259,429	271,087
Less direct donor benefit costs	(24,606)	—	—	(24,606)	(28,784)
Net campaign contributions	211,565	23,258	—	234,823	242,303
Co-pay contributions	—	43,000	—	43,000	67,100
Legacies	9,998	159	—	10,157	5,555
Donated services and media (note 6)	9,864	—	—	9,864	10,985
Net interest and dividend income	1,802	59	43	1,904	1,488
Net assets released from restrictions (note 2):					
Co-pay assistance	41,804	(41,804)	—	—	—
Satisfaction of other donor restrictions	28,755	(28,755)	—	—	—
Total operating revenue	303,788	(4,083)	43	299,748	327,431
Operating Expenses (note 10)					
<i>Program services:</i>					
Research	71,540	—	—	71,540	84,967
Patient and community service	95,526	—	—	95,526	107,578
Public health education	36,249	—	—	36,249	46,837
Professional education	16,829	—	—	16,829	19,327
Total program services	220,144	—	—	220,144	258,709
<i>Supporting services:</i>					
Management and general	31,006	—	—	31,006	29,723
Fund raising	46,205	—	—	46,205	51,100
Total supporting services	77,211	—	—	77,211	80,823
Total operating expenses	297,355	—	—	297,355	339,532
Change in net assets from operating activities	6,433	(4,083)	43	2,393	(12,101)
Write-off of contribution receivable (note 5)	—	—	—	—	(3,507)
Foreign currency translation adjustment	(530)	—	—	(530)	(153)
Net (decrease) increase in fair value of investments (note 3)	(1,897)	240	72	(1,585)	12,402
Change in net assets	4,006	(3,843)	115	278	(3,359)
Net Assets					
Beginning of year	68,842	27,989	3,575	100,406	103,765
End of year	\$ 72,848	24,146	3,690	100,684	100,406

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES


The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative totals for the year ended June 30, 2014) (In thousands)

	Program Services					Supporting Services			Total		Direct Donor Benefit Costs	
	Research	Patient and community service	Public health education	Professional education	Total	Management and general	Fund raising	Total	2015	2014	2015	2014
Awards and grants (note 2)	\$ 53,717	—	—	—	53,717	—	—	—	53,717	63,716	—	—
Therapy acceleration program (note 2)	13,503	—	—	—	13,503	—	—	—	13,503	16,107	—	—
Financial aid to patients	—	430	—	—	430	—	—	—	430	2,524	—	—
Co-pay assistance (note 2)	—	41,804	—	—	41,804	—	—	—	41,804	49,246	—	—
Co-pay processing fees	—	4,581	—	—	4,581	—	—	—	4,581	4,567	—	—
Donated services and media (note 6)	556	3,912	540	—	5,008	—	4,856	4,856	9,864	10,985	—	—
Salaries	2,457	20,103	16,184	9,094	47,838	12,055	13,084	25,139	72,977	77,557	—	—
Employee benefits and taxes (note 8)	160	4,390	3,473	1,380	9,403	3,986	3,130	7,116	16,519	21,135	—	—
Temporary services	114	1,754	1,453	596	3,917	1,156	1,149	2,305	6,222	6,568	—	—
Occupancy (note 9)	26	2,793	2,347	747	5,913	1,822	1,831	3,653	9,566	9,104	—	—
Insurance	3	199	90	—	292	244	129	373	665	674	—	—
Telephone	7	720	339	257	1,323	416	537	953	2,276	3,285	—	—
Travel	129	1,419	1,328	622	3,498	753	963	1,716	5,214	5,479	2,630	4,432
Printing, advertising, and supplies	41	3,454	2,960	1,132	7,587	2,202	7,657	9,859	17,446	22,215	4,181	5,017
Equipment rentals and maintenance	3	1,136	613	434	2,186	724	670	1,394	3,580	3,276	—	—
Postage and shipping	1	1,438	1,260	166	2,865	285	4,261	4,546	7,411	8,665	—	—
Meetings	537	459	712	415	2,123	277	240	517	2,640	4,116	11,135	11,179
Professional fees	282	4,696	3,593	1,760	10,331	3,889	6,024	9,913	20,244	23,109	1,299	1,741
Miscellaneous	1	893	622	207	1,723	716	477	1,193	2,916	3,215	5,361	6,415
Depreciation and amortization	3	1,345	735	19	2,102	2,481	1,197	3,678	5,780	3,989	—	—
Total expenses	\$ 71,540	95,526	36,249	16,829	220,144	31,006	46,205	77,211	297,355	339,532	24,606	28,784

See accompanying notes to consolidated financial statements.

EXPENSES

Research	24.0%
Patient and Community Service	32.1%
Public Health Education	12.2%
Professional Education	5.7%
Total Program Services	74.0%
Management and General	10.4%
Fund raising	15.6%
Total Supporting Services	26.0%
TOTAL EXPENSES	100.0%



CONSOLIDATED STATEMENT OF CASH FLOWS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts for the year ended June 30, 2014) (In thousands)

	2015	2014
Cash flows from operating activities:		
Change in net assets	\$ 278	(3,359)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Net decrease (increase) in fair value of investments	1,585	(12,402)
Depreciation and amortization	5,780	3,989
Provision for uncollectible accounts	126	(304)
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	(687)	193
Legacies and contributions receivable	(2)	(783)
Accounts payable and accrued expenses	(2,269)	(703)
Deferred revenue	(8,943)	(8,329)
Awards and grants payable	(14,866)	9,376
Co-Pay assistance payable	(2,233)	9,461
Net cash used in operating activities	<u>(21,231)</u>	<u>(2,861)</u>
Cash flows from investing activities:		
Purchases of fixed assets	(4,002)	(9,740)
Purchases of investments	(36,640)	(77,132)
Sales of investments	85,999	91,204
Net cash provided by investing activities	<u>45,357</u>	<u>4,332</u>
Net increase in cash and cash equivalents	24,126	1,471
Cash and cash equivalents at beginning of year	28,771	27,300
Cash and cash equivalents at end of year	<u>\$ 52,897</u>	<u>28,771</u>

See accompanying notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

1] Organization and Summary of Significant Accounting Policies

A] ORGANIZATION

The Leukemia & Lymphoma Society, Inc. (LLS) is the world's largest voluntary health agency dedicated to finding cures for blood cancers. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today's most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information for blood cancer, education and support, and influences policies that accelerate the development and approval of new blood cancer therapies. LLS advocates for blood cancer patients and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

B] TAX-EXEMPT STATUS

LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS recognizes the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to LLS's exempt purpose is subject to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years ended June 30, 2015 and 2014.

C] PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty-four chapters in the United States, and LLS's not-for-profit affiliates, LLSC and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc., and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

D] ESTIMATES

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS's management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of expenses, and valuation of donated services and media. Actual results could differ from those estimates.

E] RISKS AND UNCERTAINTIES

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS's principal source of revenue is amounts contributed by the general public. Accordingly, LLS's operations are affected by individual contributions, which are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2015 and 2014 was funded by eight and six donors, respectively.

F] SUMMARIZED FINANCIAL INFORMATION

The consolidated financial statements are presented with 2014 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2014 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS's 2014 consolidated financial statements from which the summarized information was derived.

G] SUBSEQUENT EVENTS

LLS evaluated subsequent events after the balance sheet date of June 30, 2015 through October 21, 2015, which was the date the consolidated financial statements were issued, and noted one additional required disclosure.

On September 15, 2015, LLS entered into a 15 year lease for 41,868 square feet of space for its National Office beginning no earlier than April 1, 2016. The lease terms provide for one year of rent abatement. Future minimum rental lease commitments under the lease are approximately \$1,005,000 annually for the next five years.

H] NET ASSET CLASSIFICATIONS

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS's Board of Directors, for LLS to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds are recorded as temporarily restricted net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

I] FOREIGN CURRENCY TRANSLATION

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

J] FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 unobservable inputs for the asset or liability.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

LLS follows the provisions of Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses, and grants payable approximates fair value because of their short term nature.

In 2015, LLS early adopted the provisions of Accounting Standards Update No. 2015-07, *Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent)*, which removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient and removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. LLS applied the provision of the update retrospectively to 2014.

K] CONTRIBUTIONS, GRANTS AND DEFERRED REVENUE

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

L] DONATED SERVICES

LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense.

M] DONATED MEDIA

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the financial statements, was estimated based on the placement, audience, and demographics of the PSAs.

N] CASH EQUIVALENTS

Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

O] INVESTMENTS

Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

P] FIXED ASSETS AND DEPRECIATION

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

Q] PROFESSIONAL FEES

Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

R] RECLASSIFICATIONS

Certain reclassifications of 2014 amounts have been made to conform to the 2015 presentation.

2] Research and Co-Pay Assistance Program

LLS has various activities that are utilized to carry out its mission as presented below:

RESEARCH

Awards and Grants: Awards and grants for research are approved by LLS's Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS's Board of Directors. LLS has multi-year grant commitments of \$51,612,000 at June 30, 2015 which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of \$69,335,000 and \$84,201,000 at June 30, 2015 and 2014, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately \$3,104,000 and \$821,000 as of June 30, 2015 and 2014, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP): TAP is LLS's strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS's Board of Directors. LLS has contract commitments of \$20,842,000 and \$28,575,000 at June 30, 2015 and 2014, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

Year ending June 30:

2016	\$ 40,749
2017	22,279
2018 and thereafter	9,426
Total	<u>\$ 72,454</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

CO-PAY ASSISTANCE PROGRAM

Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized \$7,254,000 and \$11,707,000 in temporarily restricted revenue as of June 30, 2015 and 2014, respectively, for which the corresponding expense is not recognized until the subsequent fiscal year as patients are approved in the program. The Co-Pay Assistance payable of \$14,465,000 and \$16,698,000 has been established based on approved patient applications received through June 30, 2015 and 2014, respectively. At June 30, 2015, temporarily restricted net assets include \$7,254,000 received in 2015 which are available for expenditure and are intended to be awarded in fiscal 2016.

The following summarizes the activities of the Co-Pay Assistance program in 2015 and 2014.

	2015	2014
Beginning balance	\$ 11,707	-
Grant commitments	43,000	67,100
Amount expended during the year:		
Direct assistance to patients	(41,804)	(49,246)
Other expenses incurred and reimbursed under the contract	(5,649)	(6,147)
Amounts available for expenditures in the next year	<u>\$ 7,254</u>	<u>11,707</u>

3] Investments

The following tables present LLS's fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2015 and 2014 (in thousands):

	2015	Level 1	Level 2	Level 3
Money market funds and cash	\$ 18,544	18,544	-	-
Fixed income:				
Long duration fixed income (mutual fund)	27,599	27,599	-	-
Short duration fixed income (mutual fund)	30,222	30,222	-	-
Government securities and other	958	958	-	-
Equities:				
Large cap equity	7,577	7,577	-	-
International equity	5,355	5,355	-	-
Small/mid cap equity	223	233	-	-
	<u>\$ 90,478</u>	<u>90,478</u>	<u>-</u>	<u>-</u>
Investments report at net asset value:				
U.S. Treasury Inflation-Protected Security fund	1,327			
Multistrategy hedge funds	38,075			
Long/short equities	2,423			
Real assets	5,638			
Total investments report at net asset value	<u>47,463</u>			
	<u>\$137,941</u>			

	2014	Level 1	Level 2	Level 3
	\$ 25,633	25,633	-	-
Money market funds and cash				
Fixed income:				
Long duration fixed income (mutual fund)	55,513	55,513	-	-
Short duration fixed income (mutual fund)	33,923	33,923	-	-
Government securities	1,057	1,057	-	-
Equities:				
Large cap equity	5,594	5,594	-	-
International equity	6,905	6,905	-	-
Small/mid cap equity	1,717	1,717	-	-
	<u>\$130,342</u>	<u>130,342</u>	<u>-</u>	<u>-</u>
Investments report at net asset value:				
U.S. Treasury Inflation-Protected Security fund	2,374			
Multistrategy hedge funds	40,769			
Long/short equities	3,705			
Real assets	8,826			
Limited partnership equity indices	2,869			
Total investments report at net asset value	<u>58,543</u>			
	<u>\$188,885</u>			

In 2015, LLS liquidated approximately \$50,000,000 of its investment portfolio in anticipation of funding grant commitments in fiscal 2016 as discussed in note 2. Such amount is included in cash and cash equivalents at June 30, 2015.

Investment expenses of \$866,000 and \$1,338,000 have been netted against the net (decrease) increase in fair value of investments for the years ended June 30, 2015 and 2014, respectively. The unrealized (losses) gains were \$(4,851,000) and \$6,573,000 for the years ended June 30, 2015 and 2014, respectively.

LLS's alternative investments are diversified across four investment strategies, as follows:

1. *Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.
2. *Long/short equities* – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.
3. *Real asset strategy* – passively managed real asset portfolios comprise Real Estate Investment Trust Index, commodities, and global natural resource stocks.
4. *Limited partnership equity indices* – the underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS's risk with respect to such transactions is limited to its capital balance in each investment.

LLS's alternative investments contain various redemption restrictions with required written notice ranging from 1 to 90 days. By contrast, all of LLS's nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2015 and 2014, the following table summarizes the composition of such alternative investments at fair value by the various redemption provisions (in thousands):

Redemption period	2015	2014
Daily	\$ 6,965	11,200
Monthly	–	2,869
Quarterly	38,075	40,769
Annual	2,423	3,705
Total	<u>\$ 47,463</u>	<u>58,543</u>

As of June 30, 2015 and 2014, LLS has no unfunded commitments on its alternative investments.

4] Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2015 and 2014 (in thousands):

	2015		2014	
	Temporarily restricted	Permanently restricted	Temporarily restricted	Permanently restricted
Time restrictions	\$ 607	–	\$ 1,295	–
Research	11,738	3,543	10,724	3,270
Patient service	4,432	–	2,802	–
Co-pay assistance	7,254	–	11,707	–
Other	115	147	1,461	305
Total	<u>\$ 24,146</u>	<u>3,690</u>	<u>\$ 27,989</u>	<u>3,575</u>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2015 and 2014 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS's overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2015 (in thousands):

	2015		
	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,164	3,575	6,739
Investment income	61	43	104
Net appreciation	82	72	154
Appropriation for expenditure	(221)	–	(221)
Endowment net assets at June 30	<u>\$ 3,086</u>	<u>3,690</u>	<u>6,776</u>

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2014 (in thousands):

	2014		
	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,122	3,443	6,565
Investment income	44	79	123
Net appreciation	213	53	266
Appropriation for expenditure	(215)	–	(215)
Endowment net assets at June 30	<u>\$ 3,164</u>	<u>3,575</u>	<u>6,739</u>

5] Legacies and Contributions Receivable

LLS's legacies and contributions receivable at June 30, 2015 and 2014 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate which is considered a Level 3 input in the fair value hierarchy. Amounts are scheduled to be received as follows (in thousands):

	2015	2014
Less than one year	\$ 7,111	5,301
1 to 5 years	2,413	4,137
After 5 years	575	650
Subtotal	10,099	10,088
Less:		
Allowance for uncollectible accounts	(614)	(488)
Discount to present value (1.5% to 5.0%)	(496)	(487)
Total	<u>\$ 8,989</u>	<u>9,113</u>

In 2014, a foundation notified LLS that it intended to cancel a grant commitment that was made in the previous year due to a change in the foundation's objectives. Accordingly, LLS wrote off the balance of the contribution receivable in the amount of \$3,507,000.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

6] Deferred Revenue, Donated Services and Media

During 2013, LLS received a \$20,000,000 grant with the contractual agreement to be utilized on research which is jointly identified by the grantor and LLS. At June 30, 2015 and 2014, the unexpended balance of the grant of \$4,504,000 and \$13,700,000, respectively, are included in deferred revenue. Revenue under this grant is expected to be recognized over the next year, as expenses are incurred. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

	2015	2014
Donated services	\$ 4,468	\$ 4,985
Donated media	5,396	6,000
Total	<u>\$ 9,864</u>	<u>\$ 10,985</u>

7] Fixed Assets, Net

Fixed assets at June 30, 2015 and 2014 consist of the following (in thousands):

	2015	2014
Leasehold improvements	\$ 1,109	1,135
Furniture, fixtures, and other office equipment	2,629	2,646
Computer equipment and software	31,829	27,913
Total	\$ 35,567	31,694
Less accumulated depreciation and amortization	(20,741)	(15,090)
Fixed assets, net	<u>\$ 14,826</u>	<u>16,604</u>

8] Retirement Plans

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated \$1,858,000 and \$4,214,000 for the years ended June 30, 2015 and 2014, respectively.

LLS has 457 deferred compensation plans (the 457 Plans) for its executive staff. The 457 Plans are nonqualified deferred compensation plans subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plans approximated \$10,000 and \$296,000 for the years ended June 30, 2015 and 2014, respectively. The assets and liabilities of the 457 Plans are included in investments and accounts payable and accrued expenses in the accompanying consolidated balance sheet and amounted to approximately \$1,380,000 and \$1,589,000 at June 30, 2015 and 2014, respectively.

9] Lease Commitments

The leases for premises, which LLS's National Office and chapters occupy, expire on various dates through September 30, 2023 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

Year ending June 30:	
2016	\$ 7,483
2017	5,047
2018	3,625
2019	2,567
2020	2,064
Thereafter	4,321
Total	<u>\$ 25,107</u>

10] Joint Costs Allocation

For the years ended June 30, 2015 and 2014, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

	2015	2014
Fund raising	\$ 15,294	12,645
Patient and community service	1,152	1,513
Public health education	3,179	8,456
Total	<u>\$ 19,625</u>	<u>22,614</u>

NATIONAL LEADERS

Chairman of the Board

James H. Davis, PhD, JD
Palm Beach Gardens, FL

Vice Chair

Elizabeth J. (Betsy) Clark
EJC Consulting
Saugerties, NY

Secretary/Treasurer

Kenneth M. Schwartz
EY
New York, NY

At Large

Donald R. Proctor
Cisco Systems
San Jose, CA

BOARD OF DIRECTORS

James A. Beck
Hefren-Tillotson, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

Jorge L. Benitez
CEO Accenture NA, retired
Miami Beach, FL

James E. Bradner, MD
Dana-Farber Cancer Institute
Boston, MA

Peter Bennett Brock
Brock Development Corp.
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Scott A. Carroll, JD
Jackson Lewis
Cincinnati, OH

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Timothy S. Durst, JD
Baker Botts, LLP
Dallas, TX

Graciela C. Eleta
Eleta Consulting, Inc.
Guaynabo, PR

Bernard H. Garil
Delray Beach, FL

Beth E. Hawley
Cogent HMG
Wayne, PA

Francie Heller
Heller Advisory
New York, NY

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Richard M. Jeanneret
EY
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Ralph E. Lawson
Baptist Health South Florida
Coral Gables, FL

Michelle LeBeau, PhD
University of Chicago
Chicago, IL

Gilles B. Legault
Global Legal Affairs
Montreal, Quebec, Canada

Connie L. Lindsey
Northern Trust
Chicago, IL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Frank O. Smith, III, MD
Medpace
Cincinnati, OH

Kathryn C. Vecellio
Vecellio Group
Palm Beach, FL

Louise G. Warner
Chagrin Falls, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

EXECUTIVE LEADERSHIP

THE LEUKEMIA & LYMPHOMA SOCIETY

Louis J. DeGennaro, PhD
President & CEO

Danielle Gee
Chief of Staff

Andrew S. Coccarri, Jr.
Executive Vice President
Chief Product Officer

Rosemarie Loffredo
Executive Vice President
Chief Financial &
Administrative Officer

Mark Roithmayr
Executive Vice President
Chief Development Officer

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

Shelagh Tippet-Fagyas
President
Canadian Operations

OFFICES

ALABAMA

100 Chase Park South • Suite 220
Birmingham, AL 35244
205.989.0098

ALASKA

See *Washington*

ARIZONA

3877 North 7th Street • Suite 300
Phoenix, AZ 85014
602.567.7600

ARKANSAS

See *Missouri*

CALIFORNIA

1800 30th Street • 4th Floor
Bakersfield, CA 93301
661.845.2710

340 West Fallbrook Avenue
Suite 101

Fresno, CA 93711
559.435.1482

6033 West Century Boulevard
Suite 300

Los Angeles, CA 90045
310.342.5800

765 The City Drive South • Suite 450
Orange, CA 92868
714.481.5600

7750 College Town Drive • Suite 210
Sacramento, CA 95826
916.929.4720

9150 Chesapeake Drive • Suite 100
San Diego, CA 92123
858.277.1800

221 Main Street • Suite 1650
San Francisco, CA 94105
415.625.1100

675 North First Street • Suite 1100
San Jose, CA 95112-5156
408.490.2666

2455 Bennett Valley Road
Suite B204
Santa Rosa, CA 95404
707.544.4350

COLORADO

720 South Colorado Boulevard
Suite 500-S
Denver, CO 80246
720.440.8620

CONNECTICUT

100 Pearl Street
Hartford, CT 06103
203.379.0445

3 Landmark Square • Suite 330
Stamford, CT 06901
203.388.9160

DELAWARE

100 West 10th Street • Suite 209
Wilmington, DE 19801
302.661.7300

FLORIDA

200 South Park Road
Suite 140
Hollywood, FL 33012
954.744.5300

7077 Bonneval Road • Suite 103
Jacksonville, FL 32216
904.332.6414

3319 Maguire Boulevard • Suite 101
Orlando, FL 32803
407.898.0733

3230 Commerce Place • Suite B
West Palm Beach, FL 33407
561.616.8682

3507 East Frontage Road • Suite 300
Tampa, FL 33607
813.963.6461

GEORGIA

3715 Northside Parkway
Building 400 • Suite 300
Atlanta, GA 30327
404.720.7900

340 Eisenhower Drive • Suite 220
Savannah, GA 31406

HAWAII

P.O. Box 29518
Honolulu, HI 96820
808.261.3020

IDAHO

2404 West Bank Drive • Suite 103
Boise, ID 83705
208.658.6662

ILLINOIS

651 West Washington Boulevard
Suite 400
Chicago, IL 60661
312.651.7350

See also *St. Louis, MO*

INDIANA

9075 N. Meridian Street • Suite 150
Indianapolis, IN 46260
317.860.3840

IOWA

St. Luke's Hospital
1026 A Avenue NE, RC107
Cedar Rapids, IA 52406-3026
319.362.1476

2700 Westown Parkway • Suite 260
West Des Moines, IA 50266
515.270.6169

KANSAS

6811 Shawnee Mission Parkway
Cloverleaf Building #1 • Suite 202
Shawnee Mission, KS 66202-4001
913.262.1515

300 North Main • Suite 300
Wichita, KS 67202
316.266.4050

KENTUCKY

836 Euclid Avenue • Suite 316 & 317
Suite 140
Lexington, KY 40502
859.226.0764

301 East Main Street • Suite 100
Louisville, KY 40202-1077
502.584.8490

LOUISIANA

3636 South 1-10 Service Road
Suite 304
Metairie, LA 70001
504.837.0945

MAINE

See *Massachusetts*

MARYLAND

100 Painters Mill Road • Suite 800
Owings Mills, MD 21117
443.471.1600

MASSACHUSETTS

9 Erie Drive
Natick, MA 01760
508.810.1300

MICHIGAN

1471 East Twelve Mile Road
Madison Heights, MI 48071
248.581.3900

MINNESOTA

1711 Broadway Street NE
Minneapolis, MN 55413
612.259.4600

MISSOURI

1972 Innerbelt Business Center Drive
St. Louis, MO 63114
314.590.2230

See also *Shawnee Mission, KS*

MONTANA

See *Oregon*

NEBRASKA

12100 West Center Road
Building 1 • Suite 202
Omaha, NE 68144
402.344.2242

NEVADA

6280 South Valley View Boulevard
Suite 342
Las Vegas, NV 89118
702.436.4220

NEW HAMPSHIRE

See *Massachusetts*

NEW JERSEY

14 Commerce Drive • Suite 301
Cranford, NJ 07016
908.956.6600

NEW MEXICO

6100 Indian School Road NE
Albuquerque, NM 87110
505.872.0141

NEW YORK

5 Computer Drive West • Suite 100
Albany, NY 12205
518.438.3583

4043 Maple Road • Suite 105
Amherst, NY 14226
716.834.2578

1324 Motor Parkway • Suite 102
Hauppauge, NY 11749
631.370.7530

61 Broadway • Suite 400
New York, NY 10006
212.376.7100

1311 Mamaroneck Avenue • Suite 310
White Plains, NY 10605
914.949.5213

NORTH CAROLINA

401 Harrison Oaks Boulevard
Suite 200
Cary, NC 27513
919.367.4100

4530 Park Road • Suite 240
Charlotte, NC 28209
704.705.1850

NORTH DAKOTA

See *Minnesota*

OHIO

4370 Glendale-Milford Rd.
Cincinnati, OH 45242
513.698.2828

2215 Citygate Drive • Suite A
Columbus, OH 43219
614.476.7194

5700 Brecksville Road • 3rd Floor
Independence, OH 44131
216.264.5680

OKLAHOMA

500 North Broadway • Suite 250
Oklahoma City, OK 73102
405.943.8888

OREGON

9320 SW Barbur Boulevard
Suite 350
Portland, OR 97219
503.245.9866

PENNSYLVANIA

2405 Park Drive • Suite 100
Harrisburg, PA 17110
717.652.6520

100 North 20th Street • 4th Floor
Philadelphia, PA 19103
610.238.0360

333 East Carson Street • Suite 441
Pittsburgh, PA 15219
412.395.2873

RHODE ISLAND

2348 Post Road • Suite 202
Warwick, RI 02886
401.943.8888

SOUTH CAROLINA

107 Westpark Boulevard • Suite 150
Columbia, SC 29210
803.731.4060

1990 Augusta Street • Suite 600
Greenville, SC 29605
864.370.2402

941 Houston Northcutt Boulevard
Suite 203

Mt. Pleasant, SC 29464
843.881.8176

SOUTH DAKOTA

See *Minnesota*

TENNESSEE

404 BNA Drive • Suite 102
Nashville, TN 37217
615.331.2980

TEXAS

8001 Centre Park Drive • Suite 150
Austin, TX 78754
512.491.6610

8111 LBJ Freeway • Suite 425
Dallas, TX 75251
972.996.5900

1300 Summit Avenue • Suite 110
Fort Worth, TX 76102
817.288.2630

5433 Westheimer Road • Suite 300
Houston, TX 77056
713.840.0483

4311 North 10th Street • Suite D
McAllen, TX 78504
956.664.1629

1218 Arion Parkway • Suite 102
San Antonio, TX 78216
210.998.5400

UTAH

5296 Commerce Drive • Suite 101
Murray, UT 84107
801.281.6618

VERMONT

See *Albany, NY*

VIRGINIA

6350 Center Drive • Suite 216
Norfolk, VA 23502
757.459.4670

5540 Falmouth Street • Suite 101
Richmond, VA 23230
804.673.5690

WASHINGTON

123 NW 36th Street • Suite 100
Seattle, WA 98107
206.628.0777

WASHINGTON D.C.

3601 Eisenhower Avenue • Suite 450
Alexandria, VA 22304
703.399.2900

WEST VIRGINIA

See *Pittsburgh, PA*

WISCONSIN

200 South Executive Drive • Suite 203
Brookfield, WI 53005
262.790.4701

WYOMING

See *Colorado*

PUERTO RICO

Comercial 18
800 Roberto H. Todd Avenue
Suite 208
San Juan, PR 00907
787.725.2200

CANADA

Canada Corporate / Ontario
2 Lansing Square • Suite 804
Toronto, ON M2J 4P8
416.661.9541

Atlantic Canada Region
1660 Hollis Street • HS2
Halifax, NS B3J 1V7
902.422.5999

BC/Yukon Region
303-1401 West Broadway
Vancouver, BC V6H 1H6
604.733.2873

Ontario Region
804-2 Lansing Square
Toronto, ON M2J 4P8
647.253.5530

Prairies Region
316, 1212 31 Avenue NE
Calgary, AB T2E 7S8
403.263.5300

Région de Québec
705-1255 Robert Bourassa Boulevard
Montreal, QC H3B 3W1
514.875.1000

mission

cure leukemia, lymphoma, hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

Share LLS proof. Use this sticker to show your support.



ON THE COVER:

Micayla Wynn, a chronic myeloid leukemia (CML) survivor, takes a targeted oral drug therapy every day to keep her disease in check. Micayla has reached out to LLS for help paying for her regular blood tests.



1311 Mamaroneck Avenue
Suite 310
White Plains, NY 10605
914.949.5213
www.lls.org